WO2003089438A1

WO2003089438A1 - Labeled oxazinocarbazoles as diagnostic agents

Info

Publication number: WO2003089438A1
Application number: PCT/US2003/008828
Authority: WO
Inventors: Ruth Elizabeth Ten Brink; Kalpana M. Merchant; Timothy J. Mccarthy
Original assignee: Pharmacia & Upjohn Company Llc
Priority date: 2002-04-16
Filing date: 2003-04-08
Publication date: 2003-10-30
Also published as: AU2003222038A1; EP1495031A1; JP2005537226A

Abstract

The present invention provides isotopically labeled oxazinocarbazole derivatives having a ring connecting position 8 (C-8) and position 9 (N-9), and more specifically, provides compounds of formula (I) wherein R1, R2, R3 and R4 are described herein. These compounds are useful in the diagnostic analysis of diseases wherein modulation of 5-HT activity is desired.

Description

LABELED OXAZINOCARBAZOLES AS DIAGNOSTIC AGENTS

FIELD OF THE INVENTION

The present invention provides oxazinocarbazole derivatives having a ring connecting position 8 (C-8) and position 9 (N-9), and more specifically, provides compounds of formula (I) described herein below. These compounds are 5-HT ligands, and are useful for treating diseases wherein modulation of 5-HT activity is desired.

BACKGROUND OF THE INVENTION

Many diseases of the central nervous system are influenced by the adrenergic, the dopaminergic, and the serotonergic neurotransmitter systems. For example, serotonin has been implicated in a number of diseases and conditions which originate in the central nervous system. These include diseases and conditions related to sleeping, eating, perceiving pain, controlling body temperature, controlling blood pressure, depression, anxiety, schizophrenia, and other bodily states. R. W. Fuller, Biology of Serotonergic Transmission, 221 (1982); D. J. Boullin, Serotonin in Mental Abnormalities 1:316 (1978); J. Barchas, et al., Serotonin and Behavior, (1973). Serotonin also plays an important role in peripheral systems, such as the gastrointestinal system, where it has been found to mediate a variety of contractile, secretory, and electrophysiologic effects.

As a result of the broad distribution of serotonin within the body, there is a tremendous interest in drugs that affect serotonergic systems. In particular, receptor- specific agonists and antagonists are of interest for the treatment of a wide range of disorders, including anxiety, depression, hypertension, migraine, obesity, compulsive disorders, schizophrenia, autism, neurodegenerative disorders (e.g. Alzheimer's disease, Parkinsonism, and Huntington's chorea), and chemotherapy-induced vomiting. M. D. Gershon, et al., The Peripheral Actions of 5-Hydroxytryptamine, 246 (1989); P. R. Saxena, et al., Journal of Cardiovascular Pharmacology, 15:Supplement 7 (1990).

The major classes of serotonin receptors (5-HT_1-7) contain fourteen to eighteen separate receptors that have been formally classified. See Glennon, et al., Neuroscience and Behavioral Reviews, 1990, 14, 35; and D. Hoyer, et al. Pharmacol. Rev. 1994, 46, 157-203. Recently discovered information regarding subtype identity, distribution, structure, and function suggests that it is possible to identify novel, subtype specific agents, having improved therapeutic profiles (e.g. fewer side effects). For example, the 5-HT₆ receptor was identified in 1993 (Monsma et al., Mol. Pharmacol. 1993, 43, 320-327; and Ruat, M. et al., Biochem. Biophys. Res. Com. 1993, 193, 269-276). Several antidepressants and atypical antipsychotics bind to the 5-HT₆ receptor with high affinity and this binding may be a factor in their profile of activities (Roth et al, J. Pharm. Exp. Therapeut. 1994, 268, 1403-1410; Sleight et al., Exp. Opin. Ther. Patents 1998, 8, 1217-1224; Bourson et al, Brit. J. Pharm. 1998, 125, 1562-1566; Boess et al., Mol. Pharmacol 1998, 54, 577-583; Sleight et al., Brit. J. Pharmacol. 1998, 124, 556-562). In addition, the 5-HT₆ receptor has been linked to generalized stress and anxiety states (Yoshioka et al., Life Sciences 1998, 17/18, 1473- 1477). Together these studies and observations suggest that compounds that antagonize the 5-HT₆ receptor will be useful in treating disorders of the central nervous system.

Compounds of the present invention are radioligands of the 5-HT receptor (e.g., receptor-specific agonists or antagonists). Thus they are useful for identifying diseases wherein modulation of 5-HT activity is desired. Specifically, the compounds of this invention are useful in the diagnosis of psychosis, paraphrenia, psychotic depression, mania, schizophrenia, schizophreniform disorders, anxiety, migraine headache, drug addiction, convulsive disorders, personality disorders, post-traumatic stress syndrome, alcoholism, panic attacks, obsessive-compulsive disorders, and sleep disorders. The compounds of this invention are also useful to identify psychotic, affective, vegetative, and psychomotor symptoms of schizophrenia and the extrapyramidal motor side effects of other antipsychotic drugs. The compounds of this invention are also useful in the identification of eating behavior disorders.

SUMMARY OF THE INVENTION

The present invention provides a compound of formula I

I or a pharmaceutically acceptable salt or enantiomer thereof wherein

(a) H, or

(b) halo;

R₂ is

(a) H, or

(b) C_1-6 alkyl;

R₃ is

(a) -(CH₂)_m-NR₈R₉;

R^ is

(a) aryl; aryl is phenyl or naphthyl, optionally substituted with one or more R1₀; Each R₈ and R₉ is independently

(a) H,

(b) Cι_6 alkyl optionally substituted with -OH,

(c) CHO, provided that only one of R₈ and R₉ is CHO and the other is H, and (d) R₈ and R₉ taken together with the nitrogen to which they are attached form a five-, six-, or seven-membered heterocyclic ring wherein the heterocyclic ring includes an additional heteroatom N(Y);

Y is H or Ci-6 alkyl;

(a) halo,

(b) -OH,

(c) -CN,

(d) -CF₃,

(e) Cχ-₆ alkyl, or (f) -NH₂; and m is 2, 3 or 4; and wherein the compound of formula I includes an isotopic label. Examples of isotopic atoms that can be incorporated into compounds of the invention include, but are not limited to, isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorous, fluorine, iodine, and chlorine, such as ³H, ^UC, ¹⁴C, ¹⁸F, ¹²³I, and ¹²⁵I. For example, compounds such as N-methyl-2-[(l -phenyl- 1,2- dihydro [ 1 ,4] oxazino [2,3 ,4-j k] carbazol-7-yl)oxy] - 1 -ethanamine, 2- [( 1 -phenyl- 1,2- dihydro[l,4]oxazino[2,3,4-jk]carbazol-7-yl)oxy]ethanamine, N-ethyl-2-[(l-phenyl- l,2-dihydro[l,4]oxazino[2,3,4-jk]carbazol-7-yl)oxy]ethanamine, 2-[(8-chloro-l- phenyl-l,2-dihydro[l,4]oxazino[2,3,4-jk]carbazol-7-yl)oxy]ethanamine, 7-[2-(4- methylpiperazin- 1 -yl)ethoxy] - 1 -phenyl- 1 ,2-dihydro [ 1 ,4] oxazino [2,3 ,4-jk]carbazole, 2-({2-[(l-phenyl-l,2-dihydro[l,4]oxazino[2,3,4-jk]carbazol-7- yl)oxy]ethyl } amino)ethanol, N-ethyl-2-[(5-methyl- 1-phenyl- 1 ,2- dihydro[l,4]oxazino[2,3,4-jk]carbazol-7-yl)oxy]ethanamine, N,N-dimethyl-2-[(l- phenyl-l,2-dihydro[l,4]oxazino[2,3,4-jk]carbazol-7-yl)oxy]-l-ethanamine, 2-[(5- methyl- 1 -phenyl- 1 ,2-dihydro [ 1 ,4] oxazino [2,3 ,4-j k] carbazol-7-yl)oxy] - 1 -ethanamine, N,N-diethyl-2- [( 1 -phenyl- 1 ,2-dihydro [ 1 ,4] oxazino [2,3 ,4-jk] carbazol-7-yl)oxy] - 1 - ethanamine, and enantiomers and pharmaceutically acceptable salts thereof can include isotopic atoms.

The invention also provides a method of utilizing an isotopically labeled compound of formula I to perform diagnostic screening, such as positron emission tomography, single photon emission computed tomography, and nuclear magnetic resonance spectroscopy.

The compounds of the present invention are useful in diagnostic analysis of a disease or condition of the central nervous system in a mammal. The present invention further provides compounds that are useful in diagnostic analysis of a disease or condition in a mammal, such as where a 5-HT receptor is implicated and modulation of a 5-HT function is desired or where a 5-HT₆ receptor is implicated and modulation of a 5-HT₆ function is desired.

Diseases or disorders of the central nervous system include, but are not limited to the following: obesity, depression, schizophrenia, schizophreniform disorder, schizoaffective disorder, delusional disorder, a stress related disease (e.g. general anxiety disorder), panic disorder, a phobia, obsessive compulsive disorder, post- traumatic-stress syndrome, immune system depression, a stress induced problem with the urinary, gastrointestinal or cardiovascular system (e.g., stress incontinence), neurodegenerative disorders, autism, chemotherapy-induced vomiting, hypertension, migraine headaches, cluster headaches, sexual dysfunction in a mammal (e.g. a human), addictive disorder and withdrawal syndrome, an adjustment disorder, an age- associated learning and mental disorder, anorexia nervosa, apathy, an attention-deficit disorder due to general medical conditions, attention-deficit hyperactivity disorder, behavioral disturbance (including agitation in conditions associated with diminished cognition (e.g., dementia, mental retardation or delirium)), bipolar disorder, bulimia nervosa, chronic fatigue syndrome, conduct disorder, cyclothymic disorder, dysthymic disorder, fibromyalgia and other somatoform disorders, generalized anxiety disorder, an inhalation disorder, an intoxication disorder, movement disorder (e.g.,

Huntington's disease or Tardive Dyskinesia), oppositional defiant disorder, peripheral neuropathy, post-traumatic stress disorder, premenstrual dysphoric disorder, a psychotic disorder (brief and long duration disorders, psychotic disorder due to medical condition, psychotic disorder NOS), mood disorder (major depressive or bipolar disorder with psychotic features) seasonal affective disorder, a sleep disorder, a specific developmental disorder, agitation disorder, selective serotonin reuptake inhibition (SSRI) "poop out" syndrome or a Tic disorder (e.g., Tourette's syndrome).

DETAILED DESCRIPTION OF THE INVENTION The compounds of the present invention are generally named according to the

TUPAC or CAS nomenclature system. Abbreviations which are well known to one of ordinary skill in the art may be used (e.g. "Ph" for phenyl, 'Me" for methyl, "Et" for ethyl, "h" for hour or hours and "rt" for room temperature).

The carbon atom content of various hydrocarbon-containing moieties is indicated by a prefix designating the minimum and maximum number of carbon atoms in the moiety, i.e., the prefix C i__j indicates a moiety of the integer 'i" to the integer "j" carbon atoms, inclusive. Thus, for example, C_1-7alkyl refers to alkyl of one to seven carbon atoms, inclusive.

Specific and preferred values listed below for radicals, substituents, and ranges, are for illustration only; they do not exclude other defined values or other values within defined ranges for the radicals and substituents.

The following definitions are used, unless otherwise described. Halo is fluoro, chloro, bromo, or iodo. Alkyl denotes both straight and branched groups; but reference to an individual radical such as "propyl" embraces only the straight chain radical, a branched chain isomer such as "isopropyl" being specifically referred to. Specifically, C_1-7 alkyl can be methyl, ethyl, propyl, isopropyl, butyl, iso-butyl, sec-butyl, pentyl, 3- pentyl, or hexyl.

C_3-6 cycloalkyl denotes a cycloalkyl having three to six carbon atoms. Specifically, C_3-6 cycloalkyl can be cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl.

Aryl denotes a phenyl or a naphthyl radical. Optionally, aryl is substituted with one or more halo, OH, CN, CF₃, C_1-6 alkyl, or NH₂.

Pharmaceutically acceptable salts denote acid addition salts useful for administering the compounds of this invention and include, but are not limited to, hydrochloride, hydrobromide, hydroiodide, sulfate, phosphate, acetate, propionate, lactate, mesylate, maleate, malate, succinate, tartrate, citric acid, 2-hydroxyethyl sulfonate, fumarate, methanesulfonic acid salt and etc. Specifically, pharmaceutically acceptable salts can be maleate, methanesulfonic acid salt and etc.

Mammal denotes human and animals.

A specific value for Ri includes H or halo.

A specific value for Ri includes H or chloro. A specific value for R₂ includes H or C_1-6 alkyl.

A specific value for R₂ includes H, or methyl.

A specific value for R₃ includes -(CH₂)_m-NR₈R₉, wherein R₈ and R₉ are independently H, or C_1-6 alkyl optionally substituted with -OH, or where one of R₈ or R₉ is CHO and the other is H, or where R₈ and R₉ taken together with the nitrogen to which they are attached form a five-, six-, or seven-membered heterocyclic ring wherein the heterocyclic ring includes an additional heteroatom N(Y), wherein Y is H or C_1-6 alkyl.

A specific value for R₃ includes -(CH₂)₂-NR₈R₉, wherein R₈ and R₉ is independently H, C_1-4 alky, or R₈ and R₉ taken together with the nitrogen to which they are attached form piperazinyl, wherein one of the nitrogen atoms on the piperazinyl ring is substituted with H or C_1-4 alkyl. A specific value for R₃ includes -(CH₂)₂-NR₈R₉, wherein R₈ and R₉ is independently H, methyl, ethyl, ethanol, or R₈ and R taken together with the nitrogen to which they are attached form 4-methyl-l -piperazinyl.

A specific value for R₄. is phenyl. Examples of the present invention include:

N-methyl-2- [( 1 -phenyl- 1 ,2-dihydro [ 1 ,4]oxazino [2,3 ,4-jk]carbazol-7-yl)oxy]- 1 - ethanamine, 2- [( 1 -phenyl- 1 ,2-dihydro [ 1 ,4]oxazino [2,3 ,4-jk]carbazol-7-yl)oxy]ethanamine, N-ethyl-2-[( 1 -phenyl- 1 ,2-dihydro [ 1 ,4] oxazino [2,3 ,4-jk]carbazol-7-yl)oxy]ethanamine, 2-[(8-chloro-l-phenyl-l,2-dihydro[l,4]oxazino[2,3,4-jk]carbazol-7- yl)oxy]ethanamine, 7-[2-(4-methylpiperazin- 1 -yl)ethoxy]-l -phenyl- 1 ,2-dihydro[ 1 ,4]oxazino[2,3,4- jkjcarbazole, 2-( { 2- [( 1 -phenyl- 1 ,2-dihydro [ 1 ,4] oxazino [2,3 ,4-jk] carbazol-7- yl)oxy]ethyl}amino)ethanol,

N-ethyl-2-[(5-methyl- 1 -phenyl- 1 ,2-dihydro [ 1 ,4]oxazino [2,3 ,4-jk]carbazol-7- yl)oxy] ethanamine, N,N-dimethyl-2-[(l-phenyl-l,2-dihydro[l,4]oxazino[2,3,4-jk]carbazol-7-yl)oxy]-l- ethanamine, 2- [(5-methyl- 1 -phenyl- 1 ,2-dihydro[ 1 ,4] oxazino [2,3 ,4-jk]carbazol-7-yl)oxy]- 1 - ethanamine, N,N-diethyl-2-[( 1 -phenyl- 1 ,2-dihydro [ 1 ,4] oxazino [2,3 ,4-jk]carbazol-7-yl)oxy] - 1 - ethanamine, and enantiomers and pharmaceutically acceptable salts thereof having isotopic atom(s). It will be appreciated by those skilled in the art that compounds of the invention contain a chiral center, therefore, they may be isolated in optically active or racemic forms. Some compounds may exhibit polymorphism. It is to be understood that the present invention encompasses any racemic, optically active, polymorphic, tautomeric, or stereoisomeric form, or mixture thereof, of a compound of the invention, which possesses the useful properties described herein. It is well known in the art to prepare optically active forms (for example, by resolution of the racemic form by recrystallization techniques, by synthesis from optically-active starting materials, by chiral synthesis, or by chromatographic separation (using a chiral stationary phase, for example) and to determine 5-HT₆ activity using the standard tests described herein, or using other similar tests which are well known in the art.

The following Schemes describe the preparation of compounds of the present invention. All of the starting materials are commercially available or prepared by procedures described in these schemes or by procedures that would be well known to one of ordinary skill in organic chemistry. The variables used in the Schemes are as defined above or as in the claims.

Scheme A discloses several methods of preparing benzoxazine 6:

Scheme A

6

\

Nitrophenol 1 can be alkylated with an alpha halo ketone 2 using a base such as sodium carbonate, potassium carbonate, cesium carbonate, sodium bicarbonate, sodium hydride, and sodium hydroxide in solvents such as DMF, THF, acetone, dichloromethane, or acetonitrile to give nitro ether 3. Reduction of the nitro group of 3 with reducing agents such as hydrogen and palladium on carbon or tin (IT) chloride or other reducing agents (see, for example, March, J. Advanced Organic Chemistry, 3rd ed., John Wiley and Sons: New York: 1985) gives oxazine imine 5, which upon further treatment with reducing agents such as hydrogen and palladium on carbon or sodium borohydride in solvents such as ethanol, methanol, and water gives benzoxazine 6. Alternatively, oxazine imine 5 is prepared from amino phenol 4 and alpha halo ketone 2 in the presence of a phase transfer catalyst and dichloromethane and aqueous potassium carbonate (see Sabitha and Rao, Synthetic Communications 1987, 17, 341).

Benzoxazine 6 contains a chiral center. The individual enantiomers may be obtained by several methods. One method is chromatography on a chiral stationary phase to give the individual enantiomers (see Chiral Separations by Liquid Chromatography, Ahuja, S., ed., American Chemical Society, Washington, D.C.:

1991, and Chiral Separations by HPLC: Application to Pharmaceutical Compounds, Krstulovic, A.M., ed., Ellis Norwood Limited: Chicester: 1989). Another method of obtaining the enantiomers is through reduction of oxazine imine 5 with chiral reducing agents used either stoichiometrically or catalytically. One method of using a stoichiometric amount of a chiral reducing agent is to prepare the reducing agent from sodium borohydride and an N-protected L- or D-amino acid (see Atarashi, et al., J. Heterocyclic Chem. 1991, 28, 329 and Yamada et al., J. Chem. Soc. Perkin Trans. I 1983, 265). For example, the use of CBZ-L-proline in the reagent prepared according to these references gives (+)-benzoxazine 6 as the major enantiomer. Another method of preparing benzoxazine 6 in chiral form is through the use of a chiral catalyst in the presence of a reducing agent as set forth by Noyori et al. (J. Am. Chem. Soc. 1996, 118, 4916), Buchwald et al. (J. Am. Chem. Soc. 1996, 118, 6784 and Ang. Chem. Int. Ed. Engl. 1998, 37, 1103) and others. Structures 6, 7, 8 and 9 are either racemics or individual enantiomers in Scheme A and the subsequent reactions schemes. For illustration, only the racemic form is depicted.

Next, benzoxazine 6 is stirred in an acidic solvent such as TFA, acetic acid, or aq. sulfuric acid. A nitrite such as sodium nitrite, isoamylnitrite, t-butylnitrite, or n- butylnitrite is added to give N-nitrosoamine 7. N-nitrosoamine 7 is reduced with lithium aluminum hydride in ether or THF to give the hydrazine 8, which can be reacted with cyclohexane-1 ,3-dione under Fischer indole conditions to give the oxotetrahydrooxazinocarbazole 9 (see Sundberg, R.J.; Indoles, Academic Press: London; 1996, and in Hughes, D.L. Progress in the Fischer Indole Reaction: A Review. Org. Prep. Proceed. Int. 1993, 25, 609-632). When 9 is racemic, it is conveniently separated into its enantiomers by chromatography on a column packed with a chiral stationary phase and using an eluant such as isopranol/hexane. (see Chiral Separations by Liquid Chromatography, Ahuja, S., ed., American Chemical Society, Washington, D.C.: 1991, and Chiral Separations by HPLC: Application to Pharmaceutical Compounds, Krstulovic, A.M., ed., Ellis Norwood Limited: Chicester: 1989).

Schemes B, C, and D depict only the racemate, but the methods given apply as well to the individual enantiomers.

In Scheme B, phenol 12 can be prepared from structure 9 in a single step using Raney nickel in solvents such as cumene, mesitylene, 1,2,3-trimethylbenzene, 1,2,4- trimethylbenzene, decalin, and diphenyl ether at temperatures between 130-270°C to give phenol 12 directly. A second method is heating 9 in 2-(ethoxyefhoxy)ethanol at about 160-210°C in the presence of Pd on carbon or Darco, or a mixture thereof (see European patent EP839806). Scheme B

16 17

Alternatively, structure 9 is first treated with a copper (U) halide, preferably CuCl₂ or CuBr₂, in either their anhydrous or hydrated form, in solvents such as ethylene glycol, ethylene glycol/doixane, ethylene glycol/THF, DMF, acetonitrile, ethyl acetate, chloroform, acetic acid, or acetic acid/water at temperatures between 40°C and 120°C to give halo ketones 10 and 11. For a reference to this reaction, see

Matsumoto, M.; Ishida, Y.; Watanabe, N., Heterocycles 1985, 23, 165-170. A mixture of mono and dihalo ketones 10 and 11, respectively, are usually obtained with halogenating reagents such as the copper halides. Halo ketones 10 and 11 may be separated by chromatography on silica gel and carried on to 12 and 13, or they may be carried forward as a mixture in the next step and separated in at that time. The halo ketones 10 and 11 (separately or together) are then treated with lithium chloride or lithium bromide (anhydrous LiCl or LiBr are preferred, but hydrated forms also may be used) in the presence of lithium carbonate, or with potassium carbonate with or without added lithum halide salts in a solvent such as DMF at 100-270 °C to give phenols 12 and 13. Alternatively, 9 may be alkylated using an alkylating agent such as methyl iodide in the presence of a base such as NaH, KO-t-Bu, or LDA in solvents such as THF at temperature ranging from about -78°C to room temperature to give 10, which may be converted to 12 using the methods described for the direct conversion of 9 to 12.

Phenols 12 and 13 may be alkylated with various alkylating agents to give oxazino amines 16, 17, 19, 20, and 24 directly or after several steps. Which method is used will depend on the type of amine which is desired and on the availability of alkylating agents and amines. As shown in Scheme B phenols 12 and 13 are alkylated with dialkylaminoalkylchlorides in the presence of bases such as sodium hydride, potassium carbonate, cesium carbonate, or sodium carbonate in solvents such as DMF, acetonitrile, or acetone at room temperature to 120°C using methods well- known to those versed in the art to give oxazine amines 16 and 17. Alternatively, phenols 12 and 13 are alkylated with chloro or bromoalkylnitrile in the presence of bases such as sodium hydride, potassium carbonate, cesium carbonate, or sodium carbonate in solvents such as DMF, acetonitrile, or acetone to give nitriles 14 and 15. Reduction of the nitrile with borane in THF or borane-methyl sulfide complex in THF at room temperature to 80°C gives oxazino amines 16 and 17.

Scheme C discloses further functionalization of oxazino amine 16 (or 17) by several methods:

Scheme C

20

One method is acylation with acylation agents such as ethyl formate, acetic anhydride, and the like to give acyl oxazinocarbazole 18. The carbonyl group of acyl oxazinocarbazole 18 is reduced to an alkyl group using reagents such as borane in THF or borane-methyl sulfide complex in THF at room temperature to 80°C to give alkylamino oxazinocarbazole 19. Another method is reduction using lithium aluminum hydride in ethereal solvents to effect the reduction of 18 to alkylamino oxazinocarbazole 19. Another method for the preparation of oxazinocarbazole 19 is reductive animation of 16 with an equivalent amount of an aldehyde or ketone in the presence of reducing agents such as sodium cyanoborohydride or sodium triacetoxyborohydride in solvents such as dichloromethane, dichloroethane, and THF at 0 to 80°C, or Pd/C under a hydrogen atmosphere in solvents such as methanol, ethanol, or ethyl acetate, to give 19. A third method is alkylation of oxazino amine 16 with alkyl halides or mesylates or tosylates in the presence of base in solvents such as THF, acetonitrile, dichloromethane, DMF and the like using methods well known to those versed in the art, to give 19. In Scheme C, Q is hydrogen, alkyl, or aryl. Z is hydrogen or alkyl. X is halo or sulfonate. When dialkylamino oxazinocarbazole 20 is desired, a second equivalent of the same or a different aldehyde or alkylating agent is added to alkylamino oxazinocarbazole 19 using the conditions described above. Alternatively, excess alkylating agent or aldehyde or ketone may be used starting with 16 to give 20 directly. Scheme D describes two other methods of preparing mono or dialkylamino oxazines 24:

Scheme D

24 23 Phenol 12 (or 13) is alkylated with halo alkyl halides in the presence of bases such as potassium carbonate, cesium carbonate, and NaH in solvents such as DMF, acetonitrile, THF, dichloromethane, and acetone at room temperature to 120°C to give oxazine halide 21. Halo oxazine 21 is then treated with an amine in the presence of a base such as potassium carbonate, TEA, DIEA in solvents such as DMF, acetonitrile, THF, dichloromethane, or acetone at room temperature to 120°C to give amino oxazine 24. Another route to amino oxazine 24 is by way of alkylation of phenol 12 with hydroxyalkyl halide to give oxazine alcohol 22. The alcohol group is converted to a leaving group with methane sulfonyl halide or toluene sulfonyl halide to give oxazine sulfonate 23. The O-sulfonate group is then displaced by amines to give amino oxazine 24.

The invention also includes isotopically-labeled compounds, which are identical to those recited in Formula I, where one or more atoms is replaced by an atom having an atomic mass or mass number different from the atomic mass or mass number usually found in nature. Examples of isotopes that can be incorporated into compounds of the invention include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorous, fluorine, iodine, and chlorine, such as ³H, ^UC, ¹⁴C, ¹³N, ¹⁵0, ¹⁸F, ⁹⁹ Tc, ¹²³I, and ¹²⁵I. Compounds of the present invention and pharmaceutically acceptable salts and prodrugs of said compounds that contain the aforementioned isotopes and/or other isotopes of other atoms are within the scope of the invention. Isotopically- labeled compounds can be prepared as follows. Carbon, nitrogen, oxygen, and fluorine atoms in a molecule may be replaced by isotopic versions of carbon, nitrogen, oxygen, and fluorine, respectively. Of particular usefulness are reagents containing isotopic carbon. For example, the primary amine of Example 2 may be alkylated with ⁿCH₃I to give [^πC]Example 8A. ^πCH₃I is in turn obtained from ^πCH₃OH which is produced in a radioisoptope facility due to its short half -life by methods well known to those versed in the radioisotope art. For example, (R)-(-)-[(l -phenyl- 1,2- dihydro[l,4]oxazino[2,3,4-jk]carbazol-7-yl)oxy]ethanamine (Example 2) may be alkylated by this method to give N-[^πC]methyl-N-(2-{[(lR)-l-phenyl-l,2- dihydro[l,4]oxazino[2,3,4-jk]carbazol-7-yl]oxy}ethyl)amine (Example 8A). ¹CH

Carbon- 13 labelled compounds are useful as well. They may be prepared, for example, by alkylation of a primary amine with ¹³CH₃I using methods well known to those versed in the art. Another method of preparing ¹³C-labelled compounds is by formylation or acylation of amines using commercially available ethyl [ Cjformate or ethyl [¹³C]acetate, respectively, to give amides, which are subsequently reduced as discussed elsewhere in this document to give amines. This is illustrated using ethyl formate and ethyl acetate by the conversion of Example 2 to Example 8A and the conversion of Example 4 to Example 6.

Isotopically-labeled compounds of the present invention are useful in drug and/or substrate tissue distribution and target occupancy assays. For example, isotopically labeled compounds are particularly useful in SPECT (single photon emission computed tomography) and in PET (positron emission tomography).

Single-photon emission computed tomography (SPECT), acquires information on the concentration of isotopically labeled compounds introduced to a mammal's body. SPECT dates from the early 1960's, when the idea of emission traverse section tomography was introduced by D.E. Kuhl and R.Q. Edwards prior to either PET, x-ray CT, or MRI. In general, SPECT requires isotopes that decay by electron capture and/or gamma emission. Example of viable SPECT isotopes include, but are not limited to, 123-iodine (¹²³I) and 99m-technetium (^99mTc). The nuclear decay resulting in the emission of a single gamma ray which passes through the tissue and is measured externally with a SPECT camera. The uptake of radioactivity reconstructed by computers as a tomogram shows tissue distribution in cross-sectional images.

Positron emission tomography (PET) is a technique for measuring the concentrations of positron-emitting isotopes within the tissues. Like SPECT, these measurements are, typically, made using PET cameras outside of the living subjects. PET can be broken down into several steps including, but not limited to, synthesizing a compound to include a positron-emitting isotope; administering the isotopically labeled compound to a mammal; and imaging the distribution of the positron activity as a function of time by emission tomography. PET is described, for example, by Alavi et al. in Positron Emission Tomography, published by Alan R. Liss, Inc. in 1985.

Positron-emitting isotopes used in PET include, but are not limited to, Carbon- 11, Nitrogen-13, Oxygen-15, and Fluorine-18. In general, positron-emitting isotopes should have short half-lives to help minimize the long term radiation exposure that a patient receives from high dosages required during PET imaging.

In certain instances, PET imaging can be used to measure the binding kinetics of compounds of this invention with 5-HT₆ serotonin receptors. For example, administering an isotopically labeled compound of the invention that penetrates into the body and binds to a 5-HT₆ serotonin receptor creates a baseline PET signal which can be monitored while administering a second, different, non-isotopically labeled compound. The baseline PET signal will decrease as the non-isotopically labeled compound competes for the binding to the 5-HT₆ serotonin receptor. In general, compounds of formula I that are useful in performing PET or SPECT are those which penetrate the blood-brain barrier, exhibit high selectivity and modest affinity to 5-HT₆ serotonin receptors, and are eventually metabolized. Compounds that are non-selective, exhibit excessive or small affinity for 5-HT₆ serotonin receptors, or exhibit low penetration through the blood-brain barrier are, generally, not useful in studying brain receptor binding kinetics with respect to 5-HT₆ serotonin receptors. Compounds that are not metabolized may harm the patient. Methods for determining the blood-brain penetration and the affinity for 5-HT₆ serotonin receptors are described below. Preferred compounds for isotopic labeling and use in performing PET or

SPECT include N-methyl-2-[(l-phenyl-l,2-dihydro[l,4]oxazino[2,3,4-jk]carbazol-7- yl)oxy]- 1 -ethanamine, 2- [( 1 -phenyl- 1 ,2-dihydro [ 1 ,4] oxazino [2,3 ,4-jk]carbazol-7- yl)oxy]ethanamine, N-ethyl-2-[(l-phenyl-l,2-dihydro[l,4]oxazino[2,3,4-jk]carbazol- 7-yl)oxy]ethanamine, 2-[(8-chloro-l-phenyl-l,2-dihydro[l,4]oxazino[2,3,4- jk]carbazol-7-yl)oxyjethanamine, 7-[2-(4-methylpiperazin-l-yl)ethoxyj-l-phenyl-l,2- dihydro[l,4]oxazino[2,3,4-jk]carbazole, 2-( {2- [(1 -phenyl- 1,2- dihydro[l,4]oxazino[2,3,4-jk]carbazol-7-yl)oxy]ethyl}amino)ethanol, N-ethyl-2-[(5- methyl-l-phenyl-l,2-dihydro[l,4]oxazino[2,3,4-jk]carbazol-7-yl)oxy]ethanamine, N,N-dimethyl-2- [( 1 -phenyl- 1 ,2-dihydro [ 1 ,4]oxazino [2,3 ,4-jk]carbazol-7-yl)oxy]- 1 - ethanamine, 2-[(5-methyl-l-phenyl-l,2-dihydro[l,4]oxazino[2,3,4-jk]carbazol-7- yl)oxy]- 1 -ethanamine, N,N-diethyl-2- [( 1 -phenyl- 1 ,2-dihydro [ 1 ,4]oxazino [2,3 ,4- jk]carbazol-7-yl)oxy]-l -ethanamine, and enantiomers and pharmaceutically acceptable salts thereof.

In other embodiments, nuclear magnetic resonance spectroscopy (MRS) imaging can be used to detect the overall concentration of a compound or fragment thereof containing nuclei with a specific spin. In general, the isotopes useful in MRS imaging include, but are not limited to, hydrogen-1, carbon-13, phosphorus-31, and fluorine- 19. Examples of compounds useful for MRS include N-methyl-2-[(l-phenyl- l,2-dihydro[l,4]oxazino[2,3,4-jk]carbazol-7-yl)oxy]-l-ethanamine, 2- [(1 -phenyl- 1,2- dihydro [1,4] oxazino [2, 3 ,4-jk] carbazol-7-yl)oxy] ethanamine, N-ethyl-2- [( 1 -phenyl- 1 ,2-dihydro[ 1 ,4] oxazino [2,3 ,4-jk]carbazol-7-yl)oxy]ethanamine, 2- [(8-chloro- 1 - phenyl-l,2-dihydro[l,4]oxazino[2,3,4-jk]carbazol-7-yl)oxy]ethanamine, 7-[2-(4- methylpiperazin- 1 -yl)ethoxy] - 1 -phenyl- 1 ,2-dihydro [ 1 ,4] oxazino [2,3 ,4-jk] carbazole, 2-({2-[(l-ρhenyl-l,2-dihydro[l,4]oxazino[2,3,4-jk]carbazol-7- yl)oxy]ethyl } amino)ethanol, N-ethyl-2- [(5-methyl- 1 -phenyl- 1 ,2- dihydro[l,4]oxazino[2,3,4-jk]carbazol-7-yl)oxy]ethanamine, N,N-dimethyl-2-[(l- phenyl- 1 ,2-dihydro [ 1 ,4] oxazino [2,3 ,4-jk]carbazol-7-yl)oxy]- 1 -ethanamine, 2- [(5- methyl-l-phenyl-l,2-dihydro[l,4]oxazino[2,3,4-jk]carbazol-7-yl)oxy]-l-ethanamine, N,N-diethyl-2-[( 1 -phenyl- 1 ,2-dihydro[ 1 ,4] oxazino [2,3 ,4-jk]carbazol-7-yl)oxy]- 1 - ethanamine, and enantiomers and pharmaceutically acceptable salts thereof.

Further, substitution with heavier isotopes such as deuterium, i.e., H, can afford certain therapeutic advantages resulting from greater metabolic stability, for example increased in vivo half -life or reduced dosage requirements and, hence, maybe preferred in some circumstances.

Isotopically labeled compounds of Formula I of this invention can generally be prepared by carrying out the synthetic procedures described above by substituting an isotopically labeled reagent for a non-isotopically labeled reagent. Isotopically labeled reagents are described, for example, by Langstrom in Acta Chem. Scand. S37: 147 (1990). In certain embodiments, the isotopically label is part of the R₃ substitutent of formula I and involves an alkylation of the phenols 12 and 13 described above or alkylation of the oxazino amines 16 and 17 described above. For example, an oxazino amine can be alkylated with ^πCH I to form a N-methyl oxazino amine, e.g., R₈ or R₉ in formula I is ^πCH₃. Other synthetic routes for incorporating an isotopic label can include nucleophilic fluoronation. See for example Skaddan et al., Nucl. Med. Biol. 28, 753 (2001); Hwang et al., J. Nucl. Med. 32, 1730 (1991); and McCarthy et al., J. Nucl. Med. 2002.

Pharmaceutically acceptable salts may be obtained using standard procedures well known in the art, for example by mixing a compound of the present invention with a suitable acid.

Compounds of the present invention may be administered in a pharmaceutical composition containing the compound in combination with a suitable vehicle. Such pharmaceutical compositions can be prepared by methods and contain excipients which are well known in the art. A generally recognized compendium of such methods and ingredients is Remington's Pharmaceutical Sciences by E.W. Martin (Mark Publ. Co., 15th Ed., 1975). The compounds and compositions of the present invention are administered parenterally (for example, by intravenous, intraperitoneal or intramuscular injection). The compounds or compositions may be administered by infusion or injection. Solutions of the active compound or its salts can be prepared in water, optionally mixed with a nontoxic surfactant. Dispersions can also be prepared in glycerol, liquid polyethylene glycols, triacetin, and mixtures thereof and in oils. Pharmaceutical dosage forms suitable for injection or infusion can include sterile aqueous solutions or dispersions or sterile powders comprising the active ingredient which are adapted for the extemporaneous preparation of sterile injectable or infusible solutions or dispersions, optionally encapsulated in liposomes. In all cases, the ultimate dosage form should be sterile, fluid and stable under the conditions of manufacture and storage. The liquid carrier or vehicle can be a solvent or liquid dispersion medium comprising, for example, water, ethanol, a polyol (for example, glycerol, propylene glycol, liquid polyethylene glycols, and the like), vegetable oils, nontoxic glyceryl esters, and suitable mixtures thereof. In many cases, it will be preferable to include isotonic agents, for example, sugars, buffers or sodium chloride. Sterile injectable solutions can be prepared by incorporating the active compound in the required amount in the appropriate solvent with various of the other ingredients enumerated above, as required, followed by filter sterilization. Useful liquid carriers include water, alcohols or glycols or water- alcohol/glycol blends, in which the present compounds can be dissolved or dispersed at effective levels, optionally with the aid of non-toxic surfactants.

A mammal is injected with a radioactively labeled agent at tracer doses. Tracer doses are doses sufficient to allow the receptor occupancy to be measured (e.g., to allow detection of the labeled compound) but are not sufficient to have a therapeutic effect on the mammal. Tracer dosage is between approximately 1/100 to 1/10 of the therapeutic dose. Useful dosages for unlabeled compounds of formula I can be determined by comparing their in vitro activity, and in vivo activity in animal models. Methods for the extrapolation of effective dosages in mice, and other animals, to humans are known to the art; for example, see U.S. Pat. No. 4,938,949. The therapeutic dosage range for the compound is from about 0.05 mg to about 500 mg, or any range therein, of active ingredient per unit dosage form (e.g., per kg of mammal body weight). The compound of formula I (radiolabeled) is generally administered once daily and is generally administered intravenously. For parenteral administration, the radiolabled compounds are presented in aqueous solution in a concentration of from about 0.1 to about 10%, more preferably about 0.1 to about 7%. The solution may contain other ingredients, such as emulsifiers, antioxidants or buffers. The exact regimen for administration of the compounds and compositions disclosed herein will necessarily be dependent upon the needs of the individual subject being diagnosed, of course, the judgment of the attending practitioner.

Generally, compounds of the invention are 5-HT ligands. The ability of a compound of the invention to bind or act at a 5-HT receptor, or to bind or act selectively at a specific 5-HT receptor subtype can be determined using in vitro and in vivo assays that are known in the art. As used herein, the term "bind selectively" means a compound binds at least 2 times, preferably at least 10 times, and more preferably at least 50 times more readily to a given 5-HT subtype than to one or more other subtypes. Preferred compounds of the invention bind selectively to one or more 5-HT receptor subtypes.

The ability of a compound of the invention to act as a 5-HT receptor agonist or antagonist can also be determined using in vitro and in vivo assays that are known in the art. The invention provides isotopically labeled compounds of formula I that act as either agonists or as antagonists of one or more 5-HT receptor subtypes.

The compounds and their preparations of the present invention will be better understood in connection with the following examples, which are intended as an illustration of and not a limitation upon the scope of the invention.

EXAMPLES OF PREFERRED EMBODIMENTS

PREPARATION 1 3-Phenyl-2H-l,4-benzoxazine

To potassium carbonate (72 g, 521 mmol) in water (360 mL) and CH₂C1₂ (400 mL) is added 2-aminophenol (10.05 g, 92.1 mmol) and tetra-n-butyl ammonium hydrogensulfate (0.156 g, 0.46 mmol). With vigorous stirring a solution of 2- bromoacetophenone (18.33 g, 92.1 mmol) in CH C1₂ (150 mL) is added dropwise over a period of 45 min. The mixture is allowed to stir overnight. The layers are separated and the organic layer is washed 3 times with water (300 mL), dried over magnesium sulfate and concentrated to dryness. The resulting solid is recrystallized from absolute ethanol (50 mL) to yield 11.78 g (61%) of 3-phenyl-2H-l,4- benzoxazine; mp 108-111 °C.

IR (drift) 1613, 1479, 1445, 1389, 1320, 1274, 1216, 1111, 1078, 1064, 937, 885, 754, 736, 689 cm^"1; 1H NMR (CDC1₃) δ 5.08, 6.91, 7.01, 7.13, 7.47, 7.93. Anal. Calcd for C₁₄H_πNO: C, 80.36; H, 5.30; N, 6.69. Found: C, 80.15; H, 5.34; N, 6.63.

PREPARATION 2a 3-Phenyl-3,4-dihydro-2H-l,4-benzoxazine

To a slurry of 3-phenyl-2H-l,4-benzoxazine (17 g, 81.2 mmol) in 100 mL absolute ethanol is added sodium borohydride (6.07 g, 162.4 mmol) and water (25 mL). The mixture is heated at 90 °C for 2 h. The mixture is cooled and concentrated, then partitioned between CH₂C1 and water. The organic layer is washed twice with water (200 mL), dried over magnesium sulfate and concentrated. The resulting oil is dried under high vacuum to give 15.95 g (93%) of 3-phenyl-3,4-dihydro-2H-l,4- benzoxazine. IR (liq.) 1609, 1591, 1501, 1480, 1453, 1428, 1350, 1313, 1280, 1210, 1128,

1056, 1039, 744, 700 cm^"1; 1H NMR (CDC1₃) δ 3.99, 4.28, 4.50, 6., 6.79, 6.85, 7.41.

Anal. Calcd for Cι₄H₁₃NO: C, 79.59; H, 6.20; N, 6.63. Found: C, 79.22; H, 6.27; N,

6.38.

PREPARATION 2b (3R)-3-Phenyl-3,4-dihydro-2H-l,4-benzoxazine

The product of PREPARATION 2b (5.01 g, 23.7 mmol) is dissolved in 25 ml of dichloromethane at ambient temperature and treated with N-methylmorpholine (2.3 g, 22.5 mmol). The resulting solution is stirred and cooled to -20°C. A solution of (S)-naproxen chloride (4.43 g, 17.8 mmol) in 25 ml of dichloromethane is added dropwise over 15 minutes, maintaining the reaction temperature below -17°C. The reaction mixture is stirred at -15° to -20°C for 1.5 hours and then quenched by adding 25 ml of water. The biphasic mixture is warmed to ambient temperature and stirred for 2 hours. The layers are separated and the aqueous extracted with 25 ml of dichloromethane. The organic extracts are combined and washed twice with 25 ml of saturated aqueous sodium bicarbonate, and once each with 25 ml of 1 N HCI, 25 ml of saturated sodium chloride, and 25 ml of water. The washed organic solution is dried over anhydrous sodium sulfate, filtered and then concentrated to an oil by vacuum distillation. The oil is reconstituted with 25 ml of methyl t-butyl ether and 4.8 ml of methanol. Then a solution of chlorotrimethylsilane (1.28 g, 11.9 mmol) in 7.5 ml of methyl t-butyl ether resultant solution is added dropwise to produce a thick slurry. The mixture is stirred at ambient temperature for 30 minutes, and filtered. The isolated cake is washed twice with 10 ml of methyl t-butyl ether, and dried overnight under vacuum at 50°C to provide 2.42 g of PNU-280715A (9.77 mmol, 41%) as a yellow powder.

Chiral HPLC is performed using a Chiralcel OD 250x 4.6mm column eluted at 0.5 ml/min. with a solvent mixture consisting of 25% vol. isopropanol, 75% vol. n- heptane and 0.1% vol. diethylamine. The (R)-enantiomer eluted at 17.2 min. and the (S)-enantiomer eluted at 24.6 min. Using this method, the ratio of enantiomers for the isolated PNU-280715A was determined to be 99.5: 0.5, giving an enantiomeric excess of 99% for the product.

PREPARATION 3 4-Nitroso-3-phenyl-3 ,4-dihydro-2H- 1 ,4-benzoxazine To a mixture of 3-phenyl-3,4-dihydro-2H-l,4-benzoxazine (17 g, 80.5mmol) in ethyl ether (100 mL) is added trifluoroacetic acid (6.2 mL 80.5 mmol). The resulting solution is chilled to 5 °C in an ice bath, to which n-butyl nitrite (9.4 mL 80.5 mmol) is added dropwise. The mixture is stirred for 1 h and transferred to a separatory funnel to which is slowly added potassium carbonate (2.6 g, 18.8 mmol) in water (200 mL). Solids formed in the ether layer. The layers are separated and ethyl ether (100 mL) is added to dissolve the solids. The ether layer is washed twice with water (200 mL), dried over magnesium sulfate, filtered and concentrated. The resulting oil is chilled in the refrigerator overnight. The solids formed from the oil are ground-up in hexanes and collected by filtration to give 15.7 g (81%) of 4-nitroso-3- phenyl-3 ,4-dihydro-2H- 1 ,4-benzoxazine.

IR (drift) 1493, 1467, 1438, 1321, 1305, 1288, 1243, 1230, 1151, 1118, 1062, 763, 754, 735, 728 cm^"1; 1H NMR (CDC1₃) δ 4.23, 4.56, 6.02, 7.1, 7.2, 7.3, 8.2. Anal. Calcd for C₁₄H₁₂N₂O₂: C, 69.99; H, 5.03; N, 11.66. Found: C, 69.86; H, 5.07; N, 11.57.

PREPARATION 4 3-Phenyl-2,3-dihydro-4H-l,4-benzoxazin-4-ylamine

A slurry of lithium aluminum hydride (4.9 g, 130.5 mmol) in ethyl ether (100 mL) is stirred at ice bath temperature under an argon atmosphere. A solution of 4- nitroso-3-phenyl-3,4-dihydro-2H-l,4-benzoxazine in ethyl ether (300 mL) is added dropwise over 1 h. The mixture is removed from the ice bath and allowed to stir for 18 h. Water (50 mL) is slowly added forming solids. The solids are collected by filtration and washed with ethyl ether. The resulting filtrates are combined and washed three times with water (200 mL), dried over magnesium sulfate, and concentrated to give 8.7g (61%) of 3-phenyl-2,3-dihydro-4H-l,4-benzoxazin-4- ylamine.

TR (liq.) 1585, 1491, 1462, 1453, 1351, 1309, 1283, 1267, 1243, 1215, 1046, 814, 750, 728, 702 cm^"1; 1H NMR (CDC1₃) δ 3.25, δ 4.27, 6.83, 6.92, 7.41. Anal. Calcd for C₁₄H₁₄N₂O: C, 74.31; H, 6.24; N, 12.38. Found: C, 74.48; H, 6.28; N, 11.77.

PREPARATION 5 1 -Phenyl- 1 ,2,9, 10-tetrahydro[ 1 ,4] oxazino [2,3 ,4-jk]carbazol- 7(8H)-one To a mixture of 3-phenyl-2,3-dihydro-4H-l,4-benzoxazin-4-ylamine (1.042 g,

4.6 mmol) in toluene (30 mL) is added, with stirring, cyclohexane-l,3-dione (0.538 g, 4.8 mmol). The mixture is heated to 85 °C for 15 min, at which time p- toluenesulfonic acid monohydrate (0.874 g, 4.6 mmol) is added and the temperature increased to 110 °C. The mixture is refluxed for 24 h, cooled to room temperature and concentrated. The residue is partitioned between CH C1₂/1N NaOH and the organic layer is washed with brine and dried over magnesium sulfate. Column chromatography (100 g silica gel) using (acetone/hexane (25/75)) as eluent gave 0.475g (34%) of l-phenyl-l,2,9,10-tetrahydro[l,4]oxazino[2,3,4-jk]carbazol-7(8H)- one. IR (drift) 1629, 1492, 1458, 1444, 1409, 1358, 1320, 1262, 1245, 1194, 1129,

784, 755, 736, 704 cm^"1; 1H NMR (CDC1₃) δ 2.1, 2.4, 2.5, 2.6, 4.5, 5.4, 6.8, 7.1, 7.2, 7.4 , 7.8. Anal. Calcd for C₂₀H₁₇NO₂: C, 79.18; H, 5.65; N, 4.62. Found: C, 78.85; H, 5.83; N, 4.63.

PREPARATION 6 Resolution of l-Phenyl-l,2,9,10-tetrahydro[l,4]oxazino[2,3,4- jk]carbazol-7(8H)-one

1 -Phenyl- 1 ,2,9, 10-tetrahydro [ 1 ,4]oxazino [2,3 ,4-jk]carbazol-7(8H)-one (0.600 g) is dissolved in a minimum volume of chloroform and isopropanol is added to give a final volume of 15 mL. The solution is injected onto a 5x50 cm column of 20 micron Chiralcel OD (Chiral Technologies) held at 30 °C. The sample is eluted with 30% isopropanol in heptane (V/V) at 75 mL/min while monitoring at 245 nm using a Merck/Sepracor ST-140 HPLC with closed loop peak shaving and recycling capability. About 70% of the front part of the broad peak that eluted between 25-32 minutes is collected and about 40% of the tail of the second peak that eluted between 29-37 minutes is collected. The central portions of these overlapping peaks are recycled and complete resolution is obtained on the second pass. The appropriate fractions are pooled and the solvent is removed on a rotary evaporator. The residues are assayed on a 0.46x25 cm Chiralcel OD-H column at ambient temperature using 25% isopropanol in heptane at 0.5 mL/min and detection at 244 nm. The earlier eluting enantiomer (0.297 g, R_t = 21.7 min) assayed for 97.6% ee. Chromatography on silica gel using acetone/hexane (20/80) gave 0.296 g of (R)-(-)-l-phenyl-l,2,9,10- tetrahydro[l,4]oxazino[2,3,4-jk]carbazol-7(8H)-one; [α]_D = -81° (CH₂C1₂). The later eluting enantiomer (0.261 g, R_t = 26.8 min) assayed for >99% ee. Chromatography on silica gel using acetone/hexane (20/80) gave 0.254 g of (S)-(+)-l-phenyl-l,2,9,10- tetrahydro[l,4]oxazino[2,3,4-jk]carbazol-7(8H)-one. [α]_D = +84° (CH₂C1₂).

PREPARATION 7 (S)-(+)-l-Phenyl-l,2-dihydro[l,4]oxazino[2,3,4-jk]carbazol-7- ol

A mixture of (S)-(+)-l-phenyl-l,2,9,10-tetrahydro[l,4]oxazino[2,3,4- jk]carbazol-7(8H)-one (0.397 g, 1.31 mmol), cupric chloride dihydrate (0.513 g, 3.01 mmol), and acetic acid/water (1:1, 4 mL) is heated at 120 °C for 6 h. After cooling, the mixture is partitioned between dichloromethane, water, and aq. sodium bicarbonate. The organic layers are filtered through sodium sulfate, concentrated, and stored over the weekend in the freezer. The mixture is then stirred at 130-140 °C with lithium carbonate (0.106 g, 1.44 mmol), lithium chloride (0.061 g, 1.44 mmol), and DMF (3 mL). After cooling, the mixture is partitioned between dichloromethane and sat'd aq. ammonium chloride. The organic layers are dried over sodium sulfate, concentrated, and the residue is chromatographed on silica gel gel (60 mL) using ethyl acetate/hexane (10/90) to give 0.184 g (47 % for both steps) of (S)-(+)-l -phenyl- 1,2- dihydro[l,4]oxazino[2,3,4-jk]carbazol-7-ol. [α]_D = + 98°(MeOH). PREPARATION 8 (S)-(+)-2-[(l-Phenyl-l,2-dihydro[l,4]oxazino[2,3,4- jk]carbazol-7-yl)oxy]acetonitrile

A mixture of (S)-(+)-l-Phenyl-l,2-dihydro[l,4]oxazino[2,3,4-jk]carbazol-7-ol (0.161 g, 0.534 mmol), bromoacetonitrile (0.074 mL, 1.07 mmol), potassium carbonate (0.148 g, 1.07 mmol), and DMF (2 mL) is stirred at 70 °C for 4 h.

Additional bromoacetonitrile (0.074 mL) and potassium carbonate (0.074 g) are then added and the mixture is stirred overnight. Bromoacetonitrile and potassium carbonate (0.074 mL and 0.074 g, respectively) are then added and the temperature is increased to 90 °C. The mixture is heated at that temperature for 5.5 h and then allowed to cool and stir overnight, after which the mixture is partitioned between ethyl acetate, aq. ammonium chloride, and brine. The organic layers are dried over magnesium sulfate, concentrated, and the residue is chromatographed on silica gel gel (40 mL) using first CH₂Cl /hexane (1:1) to elute unreacted starting material, and then ethyl acetate/CH₂Cl₂/hexane (5:45:50) to give 0.113 g of (S)-(+)-2-[(l -phenyl- 1,2- dihydro[l,4]oxazino[2,3,4-jk]carbazol-7-yl)oxy]acetonitrile.

[ ]_D = 118° (CH₂C1₂). Anal. Calcd for C₂₂H₁₆N₂O₂: C, 77.63; H, 4.74; N, 8.23. Found: C, 77.36; H, 4.99; N, 8.23.

EXAMPLE 1 (S)-(+)-[(l-Phenyl-l,2-dihydro[l,4]oxazino[2,3,4-jk]carbazol- 7-yl)oxy]ethanamine

A mixture of (S)-(+)-2-[(l-phenyl-l,2-dihydro[l,4]oxazino[2,3,4-jk]carbazol- 7-yl)oxy] acetonitrile (0.928 g, 0.273 mmol), borane-methyl sulfide complex (0.10 mL, 1.09 mmol), and dry THF (2 mL) is stirred at reflux for 2 h. After cooling, methanol is cautiously added to quench excess borane. The mixture is taken to dryness in vacuo and methanol is again added and removed. Dichloromethane and methanol are added to the residue and about 10 drops of cone. HCI are added. The mixture is stirred for 1 h and then taken to dryness in vacuo. The residue is partitioned between dichloromethane and aq. sodium bicarbonate. The organic layers are dried over sodium sulfate and concentrated. The residue is chromatographed on silica gel (17 mL) using methanol/dichloromethane/ammonium hydroxide (2/98/0.1%) to give 0.0774 g (82%) of (S)-(+)-[(l-phenyl-l,2-dihydro[l,4]oxazino[2,3,4-jk]carbazol-7- yl)oxy]ethanamine.

[ah = + 95°; 1H NMR (CDC1₃) δ 1.57, 3.28, 4.26, 4.50-4.66, 5.52, 6.45, 6.65, 6.96, 7.16, 7.34, 7.85. Anal. Calcd for C₂₂H2oN₂O2: C, 76.72; H, 5.85; N, 8.13. Found: C, 76.16; H, 6.12; N, 7.90.

PREPARATION 9 (R)-(-)-l-Phenyl-l,2-dihydro[l,4]oxazino[2,3,4-jk]carbazol-7- ol To (R)-(-)-l-phenyl-l,2,9,10-tetrahydro[l,4]oxazino[2,3,4-jk]carbazol-7(8H)- one (17.3 g, 57.3 mmol) in dry DMF (60 mL) is added anhydrous cupric chloride (17.7 g, 131.8 mmol) and anhydrous lithium chloride (9.6 g, 229 mmol). The mixture is heated at 60 °C for 40 h. The mixture is then poured into water (600 mL), forming solids. The solids are dissolved in ethyl acetate (50 mL) and filtered to remove inorganic solids. The filtrates are concentrated to dryness and the resulting solids are dissolved in DMF (60 mL), to which is added lithium bromide (12.4 g, 143 mmol) and lithium carbonate (10.6 g, 143 mmol). The mixture is heated at 120 °C for 6 h, cooled, then partitioned between water and CH₂CI₂, and the organic layer washed three times with water (200 mL). Column chromatography (600 mL silica) is performed using EtOAc/hexanes (20/80) as eluent. The material is then rechromatographed (600 mL silica) using EtOAc/hexane (20/80) as eluent to give 6.0 g (35%) of (R)-(-)-l-phenyl-l,2-dihydro[l,4]oxazino[2,3,4-jk]carbazol-7-ol; [ ]²⁵ _D = -121° (c 0.73, methylene chloride).

1H NMR (CDC1₃) δ 4.5, 4.6, 5., 6.4, 6.6, 7.0, 7.1, 7.2, 7.3, 7.8. Anal. Calcd for C₂₀H₁₅NO₂: C, 79.71; H, 5.02; N, 4.65. Found: C, 78.82; H, 5.14; N, 4.50.

PREPARATION 10 (R)-(-)-2-[(l-phenyl-l,2-dihydro[l,4]oxazino[2,3,4- jk]carbazol-7-yl)oxy]acetonitrile

To a mixture of (R)-(-)-l-phenyl-l,2-dihydro[l,4]oxazino[2,3,4-jk]carbazol-7- ol (5.9 g 19.6 mmol) in DMF (50 mL) is added potassium carbonate (8.1 g, 58.7 mmol) and bromoacetonitrile (4.1 mL, 58.7 mmol). The mixture is stirred at room temperature for 20 h. The mixture is partitioned between water and Et₂O. The organic layer is washed twice with water (200 mL), dried over anhydrous sodium sulfate and concentrated. Column chromatography (800 mL silica) using CH₂C1₂ eluent gave 5.94 g (89%) of (R)-(-)-2-[(l-phenyl-l,2-dihydro[l,4]oxazino[2,3,4- j k] carbazol-7-yl)oxy] acetonitrile.

[α]²⁵ _D = -115° (c 0.84, methylene chloride); IR (drift) 1586, 1497, 1456, 1452, 1321, 1311, 1262, 1237, 1177, 1152, 1041, 789, 738, 718, 700 cm^"1; 1H NMR

(CDC1₃) δ 4.5, 4.6, 5.0, 5.5, 6.5, 6.7, 7.0, 7.2, 7.3, 7.8. Anal. Calcd for C₂₂H₁₆N₂O2: C, 77.63; H, 4.74; N, 8.23 Found: C, 76.75; H, 4.72; N, 8.10.

EXAMPLE 2 (R)-(-)-[(l-Phenyl-l,2-dihydro[l,4]oxazino[2,3,4-jk]carbazol- 7-yl)oxy]ethanamine and its methanesulfonic acid salt

To a mixture of (R)-(-)-2-[(l-phenyl-l,2-dihydro[l,4]oxazino[2,3,4- jk]carbazol-7-yl)oxy]acetonitrile (5.94 g, 17.45 mmol) in THF (100 mL) is added borane-methylsulfide complex (4.97 mL, 52.35 mmol). The mixture is refluxed at 85 °C for 24 h. The mixture is removed from heat and methanol is slowly added until gas evolution ceased. The solvents are removed under vacuum. Methanol (10 mL) is added and then removed under vacuum. The residue is then dissolved in CH₂Cl₂/CH₃OH (1:2, 75 mL). Cone. HCI (10 mL) is added and the mixture is heated at 65 °C for 2.5 h. The mixture is removed from heat and neutralized with aqueous potassium carbonate. The mixture is then partitioned between water and CH₂CI₂ and the organic layer is washed twice with water (200 mL) and dried over anhydrous sodium sulfate, then concentrated. Column chromatography (450 mL silica) using CH₃OH/CH₂Cl₂ (8:92) as eluent gave 5.85 g (97%) of (R)-(-)-[(l-phenyl-l,2- dihydro[l,4]oxazino[2,3,4-jk]carbazol-7-yl)oxy]ethanamine, which is converted to the methanesulfonic acid salt to give 4.25g (55%) of (R)-(-)-[(l-phenyl-l,2- dihydro[l,4]oxazino[2,3,4-jk]carbazol-7-yl)oxy]ethanamine methanesulfonic acid salt. mp 236 °C; [ ]²⁵ _D = -37° (c 0.96, DMSO); TR (drift) 2991, 2939, 1589, 1456, 1451, 1265, 1241, 1223, 1202, 1183, 1152, 1043, 791, 735, 701 cm^"1; 1H NMR (DMSO-d₆) δ 2.69, 3.47, 4.4, 4.5, 5.5, 6.4, 6.6, 6.8, 7.0, 7.1, 7.2, 7.8. Anal. Calcd for C₂₂H₂oN₂O₂.CH₄O₃S: C, 62.71; H, 5.49; N, 6.36; S, 7.28. Found: C, 62.42; H, 5.50; N, 6.27.

PREPARATION 12 8-Chloro-l-phenyl-l,2,9,10-tetrahydro[l,4]oxazino[2,3,4- jk]carbazol-7(8H)-one

A mixture of l-phenyl-l,2,9,10-tetrahydro[l,4]oxazino[2,3,4-jk]carbazol- 7(8H)-one (0.441 g, 1.45 mmol), anhydrous CuCl₁₂ (0.430 mmol, 3.20 mmol), anhydrous LiCl (0.308 g, 7.27 mmol), and DMF (3 mL) is stirred at 65 °C for 50 h. After cooling, the mixture is stored in the refrigerator overnight and then partitioned between CH₂CI₂ and brine. The organic layers are dried over sodium sulfate and taken to dryness. Chromatography on silica gel gel (60 mL) using ethyl acetate/CH₂Cl₂/hexane (5:45:50) gave 0.349 g (71%) of 8-chloro-l -phenyl- 1,2,9, 10- tetrahydro[l,4]oxazino[2,3,4-jk]carbazol-7(8H)-one (mixture of diastereomers). Isomer 1: R_f (EtOAc/CH₂Cl₂/hexane (5:45:50): 0.33; MS (ESI+) m/z 338 (M+H)⁺; 1H NMR (CDC1₃) δ 2.44, 3.00, 4.50-4.63, 5.42, 6.82, 7.04, 7.21, 7.37, 7.78. Isomer 2: R_f (EtOAc/CH₂Cl₂/hexane (5:45:50): 0.21; MS (ESI+) m/z 338 (M+H)⁺; 1H NMR (CDC1₃) δ 2.30-2.75, 4.45-4.60, 5.40, 6.82, 7.13, 7.21, 7.41, 7.77.

PREPARATION 13 1 -Phenyl- 1 ,2-dihydro [ 1 ,4] oxazino [2,3 ,4-jk]carbazol-7-ol Method A: A mixture of 8-chloro-l-phenyl-l,2,9,10-tetrahydro[l,4]oxazino[2,3,4- jk]carbazol-7(8H)-one (0.235 g, 0.697 mmol), anhydrous LiCl (0.0355 g, 0.837 mmol), Li₂CO₃ (0.0618 g, 0.837 mmol), and DMF (1.8 mL) is stirred at 140 °C for 3.5 h. After cooling, the mixture is partitioned between CH₂CI₂ and water. The organic layers are dried over sodium sulftate, concentrated, and chromatographed on silica gel gel using EtOAc/hexane (10/90) to give 0.143 g (68%) of l-phenyl-1,2- dihydro [ 1 ,4] oxazino [2,3 ,4-jk]carbazol-7-ol.

Method B: To l-phenyl-l,2,9,10-tetrahydro[l,4]oxazino[2,3,4-jk]carbazol-7(8H)- one (4.0 g, 13.19 mmol) in ethyl acetate/ acetonitrile (30 mL/15 mL) is added trifluoroacetic acid (2 mL) and anhydrous cupric chloride (3.56 g, 26.4 mmol). The mixture is heated to reflux at 80 °C for 1.5 h. The mixture is concentrated. The residue is dissolved in ethyl acetate (50 mL) and filtered to remove inorganic solids. The filtrates are washed with saturated potassium carbonate solution followed by water, dried over magnesium sulfate and concentrated. The residue is dissolved in DMF (15 mL) to which is added lithium bromide (2.4 g, 27.7 mmol) and lithium carbonate (2.04 g, 27.7 mmol). The mixture is heated at 120 °C for 4.5 h then partitioned between water and CH₂CI₂ with the organic layer being washed twice with brine (30 mL). Column chromatography (200 g silica gel) using EtOAc/hexanes (20/80) as eluent gave 1.05g (26%) of l-phenyl-l,2-dihydro[l,4]oxazino[2,3,4- jk]carbazol-7-ol. 1H NMR (CDC1₃) δ 4.5, 4.6, 5.5, 6.4, 6.6, 7.0, 7.1, 7.2, 7.3, 7.8.

Method C: Water is decanted from wet Raney nickel (2.5 g) and toluene is added and additional water is azeotroped off under vacuum. Toluene and decalin (4 mL) are added to the damp Raney nickel and toluene is again azeotroped off. 1-Phenyl- l,2,9,10-tetrahydro[l,4]oxazino[2,3,4-jk]carbazol-7(8H)-one (0.180 g, 0.593 mmol) is added and the mixture is heated at 180°C (additional toluene/water azeotroping occurs). After 3 h, the mixture is cooled. Dichloromethane is added and the Raney nickel is removed by filtration. The filtrate is concentrated under vacuum until solids begin precipitating out. Hexane is added and the mixture is stored in the refrigerator overnight. The solids are then collected by filtration (wash with hexane) and chromatographed on silica gel gel (30 mL) using ethyl acetate/hexane (20/80) to give 0.119 g (66%) of l-phenyl-l,2-dihydro[l,4]oxazino[2,3,4-jk]carbazol-7-ol. 1H NMR (CDC13) δ 4.50-4.65, 5.36, 5.51, 6.41, 6.56, 6.97, 7.09, 7.20, 7.35,

7.84. Anal. Calcd for C₂₀H₁₅NO₂: C, 79.71; H, 5.02; N, 4.65. Found: C, 79.33; H, 5.10; N, 4.63.

Method D: A mixture of l-phenyl-l,2,9,10-tetrahydro[l,4]oxazino[2,3,4-jk]carbazol- 7(8H)-one (0.0586 g, 0.193 mmol) and 10% Pd/C (0.058 g) in 2- (ethoxyethoxy)ethanol (1 mL) is heated at 190-200 °C for 4 h and then cooled and partitioned between dichloromethane and water. The organic layers are dried over magnesium sulfate, filtered, and the filtrate is concentrated and the residue chromatographed on silica gel using ethyl acetate/hexane (20/80) to give 0.0274 g of 1-phenyl-l ,2-dihydro[l ,4]oxazino[2,3,4-jk]carbazol-7-ol. 1H NMR (CDC1₃) δ 4.57, 5.37, 5.50, 6.42, 6.56, 6.98, 7.09, 7.17, 7.35, 7.84 .

PREPARATION 14 2-[(l-Phenyl-l,2-dihydro[l,4]oxazino[2,3,4-jk]carbazol-7- yl)oxy] acetonitrile To a mixture of l-phenyl-l,2-dihydro[l,4]oxazino[2,3,4-jk]carbazol-7-ol (1.05 g 3.49 mmol) in DMF (15 mL) is added potassium carbonate (2.4 g, 17.4 mmol) and bromoacetonitrile (1.2 mL, 17.4 mmol). The mixture is heated at 85 °C for 1.5 h. The mixture is cooled and partitioned between water and Et₂θ. The organic layer is washed twice with water (200 mL), dried over magnesium sulfate and concentrated. Column chromatography (60 g silica gel) using CH₂C1₂ as eluent gave 1.1 g (92%) of 2-[(l-phenyl-l,2-dihydro[l,4]oxazino[2,3,4-jk]carbazol-7-yl)oxy]acetonitrile. mp 61 °C; TR (drift) 1587, 1496, 1460, 1452, 1432, 1321, 1311, 1262, 1237, 1152, 1042, 790, 738, 718, 700 cm^"1; 1H NMR (CDC1₃) δ 4.5, 4.6 , 5.0, 5.5, 6.5 , 6.7, 7.0, 7.2, 7.3, 7.8.

EXAMPLE 3 N,N-Diethyl-2-[(l-phenyl-l,2-dihydro[l,4]oxazino[2,3,4- jk]carbazol-7-yl)oxy]-l-ethanamine and its maleic acid salt

To a mixture of l-phenyl-l,2-dihydro[l,4]oxazino[2,3,4-jk]carbazol-7-ol

(0.048 g, 0.159 mmol), potassium carbonate (0.044 g, 0.318 mmol), and DMF (1.0 mL) at 100 °C is added diethylaminoethyl chloride hydrochloride (0.033 g, 0.191 mmol) in aliquots over 1 h. After 5.5 h, an additional 0.011 g of diethylaminoethyl chloride hydrochloride is added, and one hour later, a few crystals of sodium iodide are added. After heating for ten hours, the mixture is allowed to stir at room temperature for the remainder of the night. Additional potassium carbonate (0.022 g) and diethylaminoethyl chloride hydrochloride (0.017 g) are added and the mixture is stirred at 100 °C for 1.5 h. The major portion of the DMF is distilled off and the residue is partitioned between dichloromethane and water. The organic layers are dried over sodium sulfate and concentrated. The residue is chromatographed on silica gel (17 mL) using EtOAc/dichloromethane (30/70 to 60/40) to give 0.040 g of N,N- diethyl-2- [( 1 -phenyl- 1 ,2-dihydro [ 1 ,4] oxazino [2, 3 ,4-jk] carbazol-7-yl)oxy] - 1 - ethanamine. MS (ESI+) m/z 401 (M+H)⁺; 1H NMR (CDC1₃) δ 1.13, 2.73, 3.10, 4.31, 4.58, 5.51, 6.44, 6.65, 6.95, 7.15, 7.34, 7.88.

The maleic acid salt is prepared using maleic acid and crystallized from EtOH to give N,N-diethyl-2-[( 1 -phenyl- 1 ,2-dihydro [ 1 ,4]oxazino [2,3 ,4-jk]carbazol-7- yl)oxy]-l -ethanamine, maleic acid salt, mp 105-107 °C. Anal. Calcd for

C₂₆H₂₆N₂O₂«C₄H₄O₄: C, 69.75; H, 6.24; N, 5.42. Found: C, 69.32; H, 6.37; N, 5.28.

EXAMPLE 4 [(l-Phenyl₇l,2-dihydro[l,4]oxazino[2,3,4-jk]carbazol-7- yl)oxy]ethanamine and its methanesulfonic acid salt

To a solution of 2-[(l-phenyl-l,2-dihydro[l,4]oxazino[2,3,4-jk]carbazol-7- yl)oxy] acetonitrile (0.380 g, 1.12 mmol) in dry THF (5 mL) is added borane-methyl sulfide complex (0.317 mL, 3.35 mmol). The mixture is stirred at 75°C for 3 h; after cooling, methanol is cautiously added to quench excess borane-methyl sulfide complex. When gas evolution had ceased, the mixture is concentrated to dryness and methanol is again added and the mixture is allowed to stir overnight. Additional methanol and enough CH₂CI₂ to dissolve the solids is added, followed by cone. HCI (0.1 mL). The mixture is stirred for 2 h, then concentrated and partitioned between CH₂C1₂ and aq. sodium bicarbonate. The organic layers are taken to dryness (sodium sulfate) to give 0.307 g (80%) of [( 1 -phenyl- 1 ,2-dihydro [1 ,4] oxazino [2,3,4- jk]carbazol-7-yl)oxy]ethanamine.

1H NMR (CDC1₃) δ 1.6, 3., 4.26, 4.50-4.66, 5.52, 6.45, 6.65, 6.96, 7.16 m, 7.34, 7.85. Addition of methanesulfonic acid (0.0857 g, 0.891 mmol) to a methylene chloride solution of the above gave, after crystallization from methanol, 0.328 g of [(l-phenyl-l,2-dihydro[l,4]oxazino[2,3,4-jk]carbazol-7-yl)oxy]ethanamine, methanesulfonate salt.

Anal. Calcd for C₂₂H₂oN₂O₂ ^»CH₄O₃S: C, 62.71; H, 5.49; N, 6.36. Found: C, 62.63; H, 5.56; N, 6.29. EXAMPLE 5 N-isopropyl-N-{2-[(l-ρhenyl-l,2-dihydro[l,4]oxazino[2,3,4- jk]carbazol-7-yl)oxy]ethyl}amine and its maleic acid salt

To a solution of 2-[(l-phenyl-l,2-dihydro[l,4]oxazino[2,3,4-jk]carbazol-7- yl)oxy] acetonitrile (0.497 g, 1.46 mmol) in dry THF is added borane-methyl sulfide complex (0.42 mL, 4.38 mmol). The mixture is stirred at 80 °C for 1.75 h and then allowed to cool. Methanol is carefully added to decompose excess borane. The solution is taken to dryness in vacuo and the addition and removal of methanol is repeated. Acetone (12 mL) and 0.5 N HCI (6 mL) are added and the to the residue and the mixture is stirred at 65-70 °C for 15 min. Acetone is removed in vacuo and the residue is partitioned between dichloromethane and aq. sodium bicarbonate. The organic layer is dried over sodium sulfate, concentrated, and chromatographed on silica gel (100 mL) using methanol/dichloromethane (2/98) as eluant to give 0.278 g of [(l-phenyl-l,2-dihydro[l,4]oxazino[2,3,4-jk]carbazol-7-yl)oxy]ethanamine and 0.24 g of material which, after resubjection to borane-methyl sulfide, remained largely unchanged by TLC. Chromatography on silica gel (60 mL) using methanol/dichloromethane/ammonium hydroxide (2/98/0.1%) gave 0.068 g of N-{2- [( 1 -phenyl- 1 ,2-dihydro [ 1 ,4] oxazino [2,3 ,4-j k] carbazol-7-yl)oxy] ethyl } -2-propanamine. 1H NMR (CDC1₃) δ 1.8, 1.17 , 3.01, 3.221, 4.35, 4.49-4.65, 5.51, 6.44 , 6.66, 6.97, 7.16, 7.34, 7.82.

The maleic acid salt is prepared using maleic acid (0.0204 g maleic acid, crystallization from dichloromethane/methanol/hexane) to give N-{2-[(l-phenyl-l,2- dihydro[l,4]oxazino[2,3,4-jk]carbazol-7-yl)oxy]ethyl}-2-propanamine, maleic acid salt. Anal. Calcd for C₂₅H₂₆N₂O₂«C₄H₄O₄: C, 69.31; H, 6.02; N, 5.57. Found: C, 69.30; H, 6.16; N, 5.65.

PREPARATION 15 N-{2-[(l-Phenyl-l,2-dihydro[l,4]oxazino[2,3,4-jk]carbazol-7- yl)oxy]ethyl } acetamide

To a mixture of [(l-phenyl-l,2-dihydro[l,4]oxazino[2,3,4-jk]carbazol-7- yl)oxy]ethanamine (0.58 g, 1.68 mmol) in DMF (10 mL) is added acetic anhydride (0.17 g, 1.68 mmol) and DMAP (0.01 g, 0.082 mmol). The mixture is heated at 85 °C for 45 min, then partitioned between water and ether. The organic layer is washed twice with water, dried over magnesium sulfate and concentrated. Column chromatography (70 g silica gel) using GH^C^/acetone (80/20) as eluent gave 0.46 g (71%) of N-{2-[(l-phenyl-l,2-dihydro[l,4]oxazino[2,3,4-jk]carbazol-7- yl)oxy]ethyl}acetamide. 1H NMR (CDCI₃) δ 2., 3.9, 4.3, 4.5, 4.6, 5.5, 6.5, 6.6, 7.0, 7.2, 7.3, 7.8.

EXAMPLE 6 N-Ethyl-2-[(l-phenyl-l,2-dihydro[l,4]oxazino[2,3,4- jk]carbazol-7-yl)oxy]-l-ethanamine and its maleic acid salt

To a mixture of N-{2-[(l-phenyl-l,2-dihydro[l,4]oxazino[2,3,4-jk]carbazol-7- yl)oxy]ethyl}acetamide (0.46 g, 1.19 mmol) in dry THF (10 mL) is added borane- methylsulfide complex (0.34 mL, 3.6 mmol). The mixture is refluxed under an argon atmosphere at 85 °C for 18 h. The mixture is then cooled to room temperature and methanol is slowly added until gas evolution ceased. The solvents are removed and methanol (20 mL) is added and then removed. The residue is dissolved in methanol (20 mL), CH₂C1₂ (3 mL), and cone. HCI (3 mL) and then heated at 65 °C for 45 min. The mixture is neutralized with aqueous potassium carbonate and partitioned between water and CH₂CI₂. The organic layer is washed with water, dried over magnesium sulfate and concentrated. Column chromatography (50 g silica gel) using CH₃OH/CH₂Cl₂ (4/96) as eluent and gave 0.268 g (61 %) of a colorless oil, N-ethyl-2- [(l-phenyl-l,2-dihydro[l,4]oxazino[2,3,4-jk]carbazol-7-yl)oxy]-l-ethanamine. Conversion to the maleic acid salt gave 0.1993 g (34%) of N-ethyl-2-[(l-phenyl-l,2- dihydro[l,4]oxazino[2,3,4-jk]carbazol-7-yl)oxy]-l-ethanamine, maleic acid salt; mp 105°C.

IR (drift) 1634, 1609, 1585, 1532, 1496, 1452, 1379, 1350, 1261, 1240, 1152, 1042, 865, 790, 739 cm^"1; 1H NMR (CDCl₃) δ l.4, 3.3, 3.6, 4.5, 4.6, 6.1, 6.4, 6., 6.9, 7.1, 7.3, 7.8. Anal. Calcd for C₂₄H₂ N₂O2.C₄H₄O₄: C, 68.84; H, 5.78; N, 5.73. Found: C, 68.50; H, 5.88; N, 5.66.

EXAMPLE 7 2-[(l-Phenyl-l,2-dihydro[l,4]oxazino[2,3,4-jk]carbazol-7- yl)oxy]ethylformamide

To a mixture of [(l-phenyl-l,2-dihydro[l,4]oxazino[2,3,4-jk]carbazol-7- yl)oxy]ethanamine (0.7423 g, 2.16 mmol) in CH₂C1₂ (10 mL) is added ethylformate (2 mL). The mixture is heated for 2 h at 60 °C, removed from heat and concentrated.

Column chromatography (80 g silica gel) using CH3OH/CH2CI2 (4/96) gave 0.769 g (96%) of Example 7.

IR (drift) 1668, 1637, 1585, 1496, 1451, 1379, 1323, 1311, 1264, 1240, 1151,

1042,790,739,700cm^"1;¹HNMR(CDCl₃)δ3.9, 4.3, 4.5, 4.6, 5.5, 6.5, 6.6, 7,

7.2, 7.3, 7.8, 8.3. Anal. Calcd for C₂₃H₂oN₂O₃: C, 74.18; H, 5.41; N, 7.52. Found:

C, 73.32; H, 5.67; N, 7.03.

EXAMPLE 7a: 2-{ [(lR)-l-Phenyl-l,2-dihydro[l,4]oxazino[2,3,4-jk]carbazol-7- yl] oxy } ethylf ormamide

To a mixture of 2-{ [(lR)-l-phenyl-l,2-dihydro[l,4]oxazino[2,3,4-jk]carbazol- 7-yl]oxy Jethylamine (0.502 g, 1.46 mmol) in CH₂C1₂ (50 mL) was added ethyl formate (1.5 mL, 18.6 mmol). The mixture was refluxed for 6 h. The mixture was concentrated to dryness under reduced pressure to give 0.542 g (100%) of Example 7a.

1H NMR (CDCI₃) δ 3.93, 4.34, 4.59, 5.53, 6.47, 6.62, 6.98, 7.18, 7.35, 7.79, 8.29.

EXAMPLE 8 N-Methyl-2-[(l-phenyl-l,2-dihydro[l,4]oxazino[2,3,4- jk]carbazol-7- yl)oxy]-l -ethanamine and its maleic acid salt

To a mixture of 2-[(l-phenyl-l,2-dihydro[l,4]oxazino[2,3,4-jk]carbazol-7- yl)oxy]ethylformamide (0.769 g, 2.06 mmol) in dry THF (10 mL) is added borane- methylsulfide complex (0.59 mL, 6.2 mmol). The mixture is refluxed at 85 °C under an argon atmosphere for 19.5 h. The mixture is then cooled to room temperature and methanol is slowly added until gas evolution ceased. The solvents are removed under vacuum and methanol (10 mL) is added and then removed. The mixture is dissolved in methanol (15 mL), CH₂C1₂ (5 mL) and cone. HCI (4 mL) and then heated at 65 °C for 1.5 h. The mixture is then neutralized with aqueous potassium carbonate and partitioned between water/CH₂Cl₂. The organic layer is washed with water, dried over magnesium sulfate and concentrated. Column chromatography (80 g silica gel) using CH₂Cl₂/hexane/CH₃OH (80/17/3) as eluent gave Example 8 (0.536 g, 73%).

1H NMR (CDCl₃) δ 2.61, 3.19, 4.35, 4.57, 5.52, 6.44, 6.66, 6.96, 7.16, 7.33, 7.81.

The compound is then converted to the maleic acid salt to give 0.4718 g (48%) of N-methyl-2-[(l-phenyl-l,2-dihydro[l,4]oxazino[2,3,4-jk]carbazol-7-yl)oxy]-l- ethanamine, maleic acid salt.

1H NMR (CDCl₃) δ 2.9, 3.6, 4.5, 4.6, 5.5, 6.1, 6.4, 6.5, 6.9, 7.1, 7.3, 7.8. Anal. Calcd for C₂₃H₂₂N₂O₂.C₄H₄O₄: C, 68.34; H, 5.52; N, 5.90. Found: C, 68.32; H, 5.47; N, 5.90. EXAMPLE 8A N-Methyl-N-(2-{ [(1R)-1 -phenyl- 1,2- dihydro [ 1 ,4] oxazino [2,3 ,4-jk] carbazol-7-yl] oxy } ethyl)amine

To a mixture of 2-{ [(lR)-l-phenyl-l,2-dihydro[l,4]oxazino[2,3,4-jk]carbazol- 7-yl]oxy}ethylformamide (0.54 g, 1.1.45 mmol) in dry THF (50 mL) was added boranemethylsulfide complex (0.42 mL, 4.43 mmol). The mixture was heated to 50°C for 2 h followed by room temperature overnight. CH3OH (10 mL) was slowly added to the mixture with evolution of gas. Solvents were removed under reduced pressure. CH₃OH (10 mL) was added to the residue then removed under reduced pressure. CH₃OH (25 mL) and concentrated hydrochloric acid were added to residue and the mixture heated to 55°C for 2 h. The mixture was removed from heat, cooled to room temperature and neutralized with saturated sodium bicarbonate. The mixture was partitioned between water and ethyl acetate the layers were separated and the organic layer dried over anhydrous magnesium sulfate and concentrated. Column chromatography on silica gel (100 mL) using 5% CH₃OH in CH2CI2 gave 0.272 g (51% yield) of Example 8a.

IR (diffuse reflectance) 2928, 1585, 1497, 1450, 1430, 1323, 1311, 1264, 1239, 1151, 1040, 789, 737, 718, 700 cm^"1; Anal. Calcd for C₂3H22N₂O2+l% H₂O:

C, 76.30; H, 6.24; N, 7.74. Found: C, 76.28; H, 6.24; N, 7.70.

PREPARATION 16 8,8-Dichloro-l-phenyl-l,2,9,10-tetrahydro[l,4]oxazino[2,3,4- jk]carbazol-7(8H)-one

To a mixture of l-phenyl-l,2,9,10-tetrahydro[l,4]oxazino[2,3,4-jk]carbazol- 7(8H)-one (0.5681 g, 1.87 mmol) in ethyl acetate (10 mL) and acetonitrile (10 mL) is added trifluoroacetic acid (2 mL). Anhydrous cupric chloride (1.26 g, 9.36 mmol) is added and the mixture is heated to reflux at 95 °C for 2 h. After 5 h, additional anhydrous cupric chloride (0.63 g, 4.68 mmol) is added and the mixture is refluxed an additional hour. The mixture is then poured into CH2CI₂ (150 mL) and filtered. The filtrates are washed with aqueous potassium carbonate. The layers are separated and the organic layer is washed twice with water (200 mL), dried over magnesium sulfate and concentrated. Column chromatography (70 g silica gel) using ethyl acetate/CH₂Cl₂/hexane (5:45:50) gave 0.428 g (61%) of 8,8-dichloro-l-phenyl- l,2,9,10-tetrahydro[l,4]oxazino[2,3,4-jk]carbazol-7(8H)-one. mp l04° C. 1H NMR (CDC1₃) δ 2.6, 2.8, 2.9, 4.5, 4.6, 5.4, 6.8, 7.1, 7.2, 7.4, 7.8. Anal. Calcd for C₂₀H1₅CI₂NO₂: C, 64.53; H, 4.06; N, 3.76; Cl, 19.05. Found: C, 64.47; H, 4.13; N, 3.73.

PREPARATION 17 8-Chloro- 1 -phenyl- 1 ,2-dihydro [ 1 ,4]oxazino [2,3 ,4-jk]carbazol- 7-ol To a mixture of 8,8-dichloro-l-phenyl-l,2,9,10-tetrahydro[l,4]oxazino[2,3,4- jk]carbazol-7(8H)-one (0.4072 g, 1.09 mmol) in DMF (5 mL) is added lithium carbonate (0.242 g, 3.27 mmol) and lithium chloride (0.143 g, 3.39 mmol). The mixture is heated under an argon atmosphere at 120 °C for 1 h and then partitioned between water and CH₂CI₂. The organic layer is washed twice with water (20 mL), dried over magnesium sulfate and concentrated. Column chromatography (50 g silica gel) using ethyl acetate/hexane (20/80) as eluent gave 0.2876 g (78%) of 8-chloro-l- phenyl- 1 ,2-dihydro [ 1 ,4]oxazino [2,3 ,4-jk]carbazol-7-ol.

1H NMR (CDCI₃) δ 4.5, 4.6, 5.5, 6.1, 6.3, 7.0, 7.2, 7.4, 7.9.

PREPARATION 18 2-[(8-Chloro-l-phenyl-l,2-dihydro[l,4]oxazino[2,3,4- jk]carbazol-7-yl)oxy]acetonitrile

To a mixture of 8-chloro-l-phenyl-l,2-dihydro[l,4]oxazino[2,3,4-jk]carbazol- 7-ol (0.286 g, 0.851 mmol) in DMF (5.0 mL) is added potassium carbonate (0.59 g, 4.25 mmol) and bromoacetonitrile (0.3 mL, 4.25 mmol). The mixture is heated at 85 °C for 1 h, then cooled and partitioned between water and Et₂θ. The organic layer is washed three times with water (50 mL), dried over magnesium sulfate and concentrated. Column chromatography (60 g silica gel) using CH₂Cl₂/hexane (1/1) as eluent gave 0.2876 g (90%) of 2-[(8-chloro-l-phenyl-l,2-dihydro[l,4]oxazino[2,3,4- jk]carbazol-7-yl)oxy]acetonitrile. 1H NMR (CDCl₃) δ 4.5, 4.6, 5.1, 5.5, 6.5, 7.0, 7.2, 7.4, 7.8.

EXAMPLE 9 2-[(8-Chloro-l-phenyl-l,2-dihydro[l,4]oxazino[2,3,4- jk]carbazol-7-yl)oxy]-l -ethanamine and its maleic acid salt

To a mixture of 2-[(8-chloro-l-phenyl-l,2-dihydro[l,4]oxazino[2,3,4- jk]carbazol-7-yl)oxy]acetonitrile (0.2838 g, 0.757 mmol) in dry THF (10 mL) is added borane-methylsulfide complex (0.22 mL, 2.27 mmol). The mixture is refluxed under an argon atmosphere at 82°C for 18 h. The mixture is then cooled to rt and methanol is slowly added until gas evolution ceased. The solvents are removed under vacuum and methanol (5 mL) is added and again removed. The residue is dissolved in methanol (10 mL), CH₂C1₂ (5 mL), and cone. HCI (3 mL) and heated at 60 °C for 1 h. The mixture is neutralized with aqueous potassium carbonate and partitioned between water and CH₂CI₂. The organic layer is washed with water, dried over magnesium sulfate and concentrated. Column chromatography (50 g silica gel) using CH₃OH/CH₂Cl₂ (4/96) as eluent gave 0.080g (28%) of 2-[(8-chloro-l-phenyl-l,2- dihydro[l,4]oxazino[2,3,4-jk]carbazol-7-yl)oxy]-l-ethanamine; mp 127-128 °C.

1H NMR (DMSO-d₆) δ 3.4, 4.3, 4.7, 6.0, 6.0, 6.96, 7.04, 7.19, 7.3, 7.4, 7.8, 8.2. Anal. Calcd for C₂₆H₂₅C1₁N₂O₆»0.25(C₂H₆O₁): C, 62.85; H, 4.88; N, 5.53; CL 7.13. Found: C, 62.6; H, 4.92; N, 5.45. Conversion to the maleic acid salt gave 0.0275 g (7.3%) of 2-[(8-chloro-l-phenyl-l,2-dihydro[l,4]oxazino[2,3,4-jk]carbazol- 7-yl)oxy]-l -ethanamine, maleic acid salt; mp 171°C; 1H NMR (CDC1₃) δ 2.79, 3.66, 4.39, 4.5, 4.55, 5.38, 6.39, 6.91, 7.15, 7.36, 7.70, 8.17.

PREPARATION 19 A 7-Methyl-3-phenyl-2H- 1 ,4-benzoxazine

To potassium carbonate (63.89 g, 462 mmol) in water (300 mL) and CH2CI2 ( 200 mL) is added 6-amino-m-cresol (10.0 g, 81.2 mmol) and tetra-n-butyl ammonium hydrogensulfate (0.139 g, 0.41 mmol). With vigorous stirring a solution of 2- bromoacetophenone (16.16 g, 81.2 mmol) is added dropwise over a period of 45 min. The mixture is allowed to stir overnight. The layers are then separated and the organic layer is washed with IN NaOH (500mL) and water (2 x 300mL), dried over magnesium sulfate and concentrated. Column chromatography (400 g silica gel) using ethyl acetate/hexane (20/80) as eluent gave 8.96 g (49%) of 7-methyl-3-phenyl- 2H-l,4-benzoxazine. 1H NMR (CDCl₃) δ 2.34, 5.06, 6.74, 6.82, 7.32, 7.47, 7.92. Anal. Calcd for C₁₅H₁₃NO: C, 80.69; H, 5.87; N, 6.27. Found: C, 80.76; H, 5.88; N, 6.21.

PREPARATION 19B 7-Methyl-3-phenyl-2H-l,4-benzoxazine To a slurry of 7-methyl-3-phenyl-2H-l,4-benzoxazine ( 37.23 g, 167 mmol) in absolute ethanol (200 mL) is added sodium borohydride (12.62 g, 333 mmol). The mixture is refluxed at 95 °C for 1.5 h. The mixture is then concentrated and partitioned between CH2CI₂ and water. The organic layer is washed twice with water (500 mL), dried over magnesium sulfate and concentrated to dryness. The resulting solid is dried to give 22.53 g (60%) of 7-methyl-3-phenyl-2H-l,4-benzoxazine.

TR (drift) 3349, 3338, 1514, 1456, 1351, 1319, 1296, 1279, 1229, 1154, 1135, 870, 811, 758, 701 cm^"1; 1H NMR (CDCI₃) δ 2.25, 3.97, 4.26, 4.47, 6.62, 6.69, 7.41. Anal. Calcd for C₁₅H₁₅NO: C, 79.97; H, 6.71; N, 6.22. Found: C, 79.96; H, 6.79; N, 6.20.

PREPARATION 20 7-Methyl-4-nitroso-3-phenyl-3,4-dihydro-2H-l ,4-benzoxazine To a mixture of 7-methyl-3-phenyl-2H-l,4-benzoxazine (22.5 g, 99.87 mmol) in ethyl ether (300 mL) is added trifluoroacetic acid (7.7 mL, 99.87 mmol). The resulting solution is chilled to 5°C in an ice bath and n-butyl nitrite (12.26 mL, 99.87 mmol) is added dropwise. The mixture is stirred for 1 h; solids formed during the reaction. The solids are collected by filtration and washed with ether. The filtrates are partitioned between ether and water and the organic layers are washed three times with water (500 mL), dried over magnesium sulfate, and concentrated to dryness. The combined solids gave 23.22 g (97%) of 7-methyl-4-nitroso-3-phenyl-3,4-dihydro-2H- 1,4-benzoxazine.

IR (drift) 1499, 1445, 1360, 1326, 1306, 1256, 1232, 1156, 1143, 1134, 1068, 1058, 820, 739, 697 cm^"1; 1H NMR (CDCI₃) δ 2.36, 4.21, 4.54, 6.02, 6.87, 6.91, 7.17, 7.26, 8.06; Anal. Calcd for C₁₅H₁₄N₂O₂: C, 70.85; H, 5.55; N, 11.02. Found: C, 70.96; H, 5.65; N, 11.01.

PREPARATION 21 7-Methyl-3-phenyl-2,3-dihydro-4H-l,4-benzoxazin-4-amine

A slurry of lithium aluminum hydride (6.9 g, 183 mmol) in ethyl ether (300 mL) is stirred in an ice bath under an argon atmosphere. A solution of 7-methyl-4- nitroso-3-phenyl-3,4-dihydro-2H-l,4-benzoxazine (23.22 g, 91.3 mmol) in ethyl ether (250 mL) and dry THF (40 mL) is added dropwise over 1.5 h. The mixture is removed from the ice bath and allowed to stir for 18 h. Water (50 mL) is slowly added, forming solids. The solids are collected by filtration and washed with ethyl ether. The resulting filtrates are combined and washed three times with water (400 mL), dried over magnesium sulfate, and concentrated to dryness to give a solid. The solids are slurried in hexane, collected, and dried to give 16.5 g (69%) of 7-methyl-3~ phenyl-2,3-dihydro-4H- 1 ,4-benzoxazin-4-amine.

IR (drift) 2912, 1579, 1505, 1455, 1318, 1305, 1243, 1233, 1163, 1050, 892, 835, 804, 759, 702 cm^"1; 1H NMR (CDC1₃) δ 2.26, 4.25, 6.65, 6.72, 7.28, 7.37. Anal. Calcd for C₁₅H₁₆N₂O: C, 74.97; H, 6.71; N, 11.66. Found: C, 75.11; H, 6.70; N, 11.53.

PREPARATION 22 5-Methyl-l-phenyl-l,2,9,10-tetrahydro[l,4]oxazino[2,3,4- jk]carbazol-7(8H)-one

To a mixture of 7-methyl-3-phenyl-2,3-dihydro-4H-l,4-benzoxazin-4-amine (5.95 g, 24.8 mmol) in toluene (175 mL) is added while stirring 1,3 cyclohexandione (2.86 g, 25.5 mmol). The mixture is heated to 95 °C for 20 min, at which time p- toluenesulfonic acid monohydrate (4.71 g, 24.8 mmol) is added and the temperature is increased to 106 °C for 1 h. The mixture is refmxed for 12h, then cooled to room temperature and concentrated. The residue is partitioned between CH₂CI₂/IN NaOH. The organic layer is washed with brine, dried over magnesium sulfate and concentrated to dryness. Column chromatography (100 g silica gel) using acetone/hexane (25/75) as eluent gave 4.06 g (51%) of 5-methyl-l -phenyl- 1,2,9, 10- tetrahydro[l,4]oxazino[2,3,4-jk]carbazol-7(8H)-one; mp 171 °C.

IR (drift) 2943, 1644, 1640, 1481, 1456, 1397, 1323, 1307, 1265, 1191, 1123, 1017, 836, 763, 704 cm^"1; 1H NMR (CDC1₃) δ 2.07, 2.42, 2.47, 2.54, 2.62, 4.45, 4.54, 5.37, 6.63, 7.05, 7.36, 7.6. Anal. Calcd for C₂ιH₁₉NO₂: C, 79.47; H, 6.03; N, 4.41. Found: C, 78.72; H, 6.23; N, 5.02. PREPARATION 23 5-Methyl- 1 -phenyl- 1 ,2-dihydro [ 1 ,4] oxazino [2,3,4-jk]carbazol- 7-ol

To 5-methyl-l-phenyl-l,2,9,10-tetrahydro[l,4]oxazino[2,3,4-jk]carbazol- 7(8H)-one (9.0 g, 28.4 mmol) in ethyl acetate/ acetonitrile (150 mL/50 mL) is added trifluoroacetic acid (4 mL) and anhydrous cupric chloride (9.7 g, 56.7 mmol). The mixture is heated to reflux at 90 °C for 7 h. The mixture is poured into methylene chloride (500 mL) and filtered to remove inorganic solids. The filtrates are washed with saturated potassium carbonate solution followed by water, dried over magnesium sulfate and concentrated. The residue is dissolved in DMF (20mL) to which is added lithium bromide (4.2 g, 56.7 mmol) and lithium carbonate (4.9 g, 56.7 mmol). The mixture is heated at 119 °C for 5 h, then partitioned between water and CH₂CI₂. The organic layer is washed twice with brine (30 mL). Column chromatography (200 g silica gel) using EtOAc/hexanes (20/80) as eluent gave 1.3 g (14.5%) of 5-methyl-l- phenyl- 1 ,2-dihydro [ 1 ,4] oxazino [2,3 ,4-jk]carbazol-7-ol. TJR (drift) 3407, 1489, 1463, 1446, 1382, 1332, 1296, 1275, 1132, 1117, 1024,

841, 752, 744, 704 cm^"1; ¹H NMR (CDCl₃) δ 2.55, 4.47, 4.58, 6.37, 6.53, 6.81, 7.03, 7.17, 7.34, 7.63. Anal. Calcd for C₂ιH₁₇NO₂: C, 79.98; H, 5.43; N, 4.44. Found: C, 79.22; H, 5.50; N, 4.34.

PREPARATION 24 2-[(5-Methyl-l-phenyl-l,2-dihydro[l,4]oxazino[2,3,4- jk]carbazol-7-yl)oxy]acetonitrile

To a mixture of 5-methyl-l-phenyl-l,2-dihydro[l,4]oxazino[2,3,4-jk]carbazol- 7-ol (1.3 g , 4.12 mmol) in DMF (15 mL) is added potassium carbonate (2.8 g, 20.6 mmol) and bromoacetonitrile (1.4 mL, 20.6 mmol). The mixture is heated at 85 °C for 1.5 h. The mixture is cooled and partitioned between water and CH2CI2. The organic layer is washed twice with water (200mL), dried over magnesium sulfate and concentrated. Column chromatography (100 g silica gel) using ethyl acetate/hexanes (20/80) eluent gave 0.665 g (46%) of 2- [(5-methyl-l -phenyl- 1,2- dihydro[ 1 ,4] oxazino [2,3 ,4-jk]carbazol-7-yl)oxy] acetonitrile. IR (drift) 1594, 1488, 1465, 1448, 1333, 1313, 1274, 1259, 1238, 1177, 1162,

1139, 1025, 749, 701 cm^"1; 1H NMR (CDCI3) δ 4.49, 4.61, 5.03, 5.53, 6.54, 6.70, 6.98, 7.17, 7.36, 7.82. Anal. Calcd for C₂3H₁₈N₂O₂: C, 77.95; H, 5.12; N, 7.90. Found: C, 77.34; H, 5.19; N, 7.61. EXAMPLE 10 2-[(5-Methyl-l-phenyl-l,2-dihydro[l,4]oxazino[2,3,4- jk]carbazol-7-yl)oxy]- 1 -ethanamine

To a mixture of 2-[(5-methyl-l-phenyl-l,2-dihydro[l,4]oxazino[2,3,4- jk]carbazol-7-yl)oxy]acetonitrile (0.66 g, 1.86 mmol) in dry THF (120mL) is added borane-methylsulfide complex (0.53 mL, 5.6 mmol). The mixture is refluxed at 85 °C for 18 h. The mixture is removed from heat and methanol is slowly added until gas evolution ceased. The solvents are removed under vacuum and methanol (5 mL) is added and again removed. The residue is dissolved in CH₂Cl₂/CH OH (1:2 15 mL). Cone. HCI (2 mL) is added and the mixture heated at 65 °C for 1 h. The mixture is removed from heat and neutralized with aqueous potassium carbonate then partitioned between water and CH2CI2. The organic layer is washed with water, dried over magnesium sulfate, and concentrated. Column chromatography (70 g silica gel) using CH₃OH/CH₂CI₂ (4:96) as eluent gave 0.444 g (67%) of 2-[(5-methyl-l-phenyl-l,2- dihydro[l,4]oxazino[2,3,4-jk]carbazol-7-yl)oxy]-l-ethanamine.

TR (drift) 1593, 1576, 1487, 1448, 1335, 1313, 1261, 1162, 1138, 1129, 1022, 838, 779, 750, 702 cm^"1; ¹H NMR (CDCl₃) δ 3.30, 4.25, 4.46, 4.57, 5.48, 6.42, 6.59, 6.93, 7.15, 7.32, 7.83. Anal. Calcd for C₂₃H22N₂O₂: C, 77.07; H, 6.19; N, 7.82. Found: C, 76.62; H, 6.29; N, 7.68.

PREPARATION 25 N- { 2-[(5-Methyl-l-phenyl- 1 ,2-dihydro[ 1 ,4]oxazino[2,3,4- jk]carbazol-7-yl)oxy]ethyl } acetamide

To a mixture of 2-[(5-methyl-l-phenyl-l,2-dihydro[l,4]oxazino[2,3,4- jk]carbazol-7~yl)oxy]-l-ethanamine (0.0.442 g, 1.23 mmol) in DMF (lOmL) is added acetic anhydride (0.126 g, 1.23 mmol) and DMAP (0.08 g, 0.66 mmol). The mixture is heated at 95 °C for 1 h and then partitioned between water and ether after cooling. The organic layer is washed three times with water (60 mL), dried over magnesium sulfate and concentrated to give 0.49 g (99%) of N-{ 2- [(5-methyl-l -phenyl- 1,2- dihydro [ 1 ,4]oxazino [2,3 ,4-jk]carbazol-7-yl)oxy]ethyl } acetamide. IR (drift) 1662, 1655, 1646, 1593, 1574, 1551, 1506, 1487, 1448, 1335, 1312,

1258, 1138, 750, 703 cm^"1; 1H NMR (CDCl₃) δ 2.03, 3.87, 4.32, 4.50, 4.61, 5.52, 6.46, 6.62, 6.97, 7.18, 7.33, 7.79. Anal. Calcd for C₂₅H₂₄N₂O₃: C, 74.98; H, 6.04; N, 6.99. Found: C, 74.56; H, 6.06; N, 6.80.

EXAMPLE 11 N-Ethyl-2-[(5-methyl-l-phenyl-l,2-dihydro[l,4]oxazino[2,3,4- jk]carbazol-7-yl)oxy]-l-ethanamine and its maleic acid salt

To a mixture of N-{2-[(5-methyl-l-phenyl-l,2-dihydro[l,4]oxazino[2,3,4- jk]carbazol-7-yl)oxy]ethyl} acetamide (0.212 g, 0.53 mmol) in THF (lOmL) is added borane-methylsulfide complex (0.15 mL, 1.6 mmol). The mixture is refluxed at 85 °C for 16 hours. After cooling, methanol is slowly added until gas evolution ceased. The solvents are removed under vacuum and methanol (5 mL) is added then removed. The residue is dissolved in CH₂Cl₂/CH₃OH (1:5, 15 mL). Cone. HCI is added and the mixture is heated at 65 °C for 1 h. The mixture is removed from heat, neutralized with aqueous potassium carbonate and then partitioned between water and CH₂C1₂. The organic layer is washed with water, dried over magnesium sulfate, and concentrated. Column chromatography (70 g silica gel) using CH OH/CH₂Cl₂ (5:95) as eluent gave 0.148 g (70%) of N-ethyl-2-[(5-methyl-l-phenyl-l,2- dihydro[l,4]oxazino[2,3,4-jk]carbazol-7-yl)oxy]-l-ethanamine (TLC: MeOH/CH2Cl₂, 5/95, Rf = 0.38); conversion to the maleic acid salt and recrystallizing from absolute ethanol gave 0.0223g of N-ethyl-2- [(5-methyl-l -phenyl- 1,2- dihydro[l,4]oxazino[2,3,4-jk]carbazol-7-yl)oxy]-l-ethanamine, maleic acid salt.

IR (drift) 1593, 1573, 1485, 1457, 1448, 1351, 1337, 1318, 1257, 1140, 1130, 1031, 866, 748, 721 cm^"1; 1H NMR (CDCl₃) δ 1.42, 2.5, 3.3, 3.59, 4.43, 4.53, 5.43, 6.41, 6.51, 6.79, 7.09, 7.31, 7.55. Water (KF): 0.24%. Anal. Calcd for C₂₅H₂₆N₂O2»C₄H₄O₄«0.24% water: C, 69.14; H, 6.03; N, 5.56. Found: C, 68.84; H,

6.12; N, 5.47.

PREPARATION 26 7-(2-chloroethoxy)-l-phenyl-l,2-dihydro[l,4]oxazino[2,3,4- jk]carbazole

To a mixture of l-phenyl-l,2-dihydro[l,4]oxazino[2,3,4-jk]carbazol-7-ol (3.0 g 9.96 mmol) and potassium carbonate (6.9 g, 50 mmol) in dry DMF (70 mL) is added l-bromo-2-chloroethane (4.0 mL, 50 mmol). The mixture is heated to 85 °C for 8.25 h. The mixture is then partitioned between water and Et₂O. The organic layer is separated and washed three times with water (100 mL), dried over anhydrous sodium sulfate, filtered and concentrated. Column chromatography (200 mL silica) using CH₂Cl₂/hexanes (1/1) as eluent gave 3.4 g (94%) of 7-(2-chloroethoxy)-l -phenyl- 1,2- dihydro[l,4]oxazino[2,3,4-jk]carbazole.

IR (drift) 1637, 1585, 1496, 1450, 1431, 1323, 1311, 1265, 1239, 1151, 1041, 790, 738, 718, 700 cm^"1; ¹H NMR (CDCl₃) δ 4.04, 4.55, 4.64, 5.5, 6.5, 6.6, 7.0, 7.2, 7.4, 7.9.

EXAMPLE 13 1 -Phenyl- l,2-dihydro[ 1,4] oxazino [2,3, 4-jk]carbazol-7-yl 2-(l- piperazinyl)ethyl ether

To a mixture of tert-butyl 4-{2-[(l-phenyl-l,2-dihydro[l,4]oxazino[2,3,4- jk]carbazol-7-yl)oxy]ethyl}-l-piperazinecarboxylate (0.406 g, 0.79 mmol) in CH₂CI₂

(2 mL) is added trifluoroacetic acid (2mL). The mixture is stirred at room temperature for 1 h then partitioned between CH₂CI₂ and water. The organic layer is washed with saturated potassium carbonate, dried over anhydrous sodium sulfate and concentrated. Column chromatography (50 mL silica) using CH OH/CH₂Cl₂ (8/92) with 2 drops per 100 mL of NH₄OH gave 0.133 g (35%) of l-phenyl-1,2- dihydro[l,4]oxazino[2,3,4-jk]carbazol-7-yl 2-(l-piperazinyl)ethyl ether; mp 72 °C.

IR (drift) 2936, 2817, 1585, 1497, 1451, 1431, 1322, 1310, 1265, 1240, 1151, 790, 738, 718, 700 cm^"1; 1H NMR (CDC1₃) δ 2.8, 3.0, 4.4, 4.5, 4.6, 5.5, 6.4, 6.6, 7.0, 7.2, 7.4, 7.9. Water (KF), 1.64%. Anal. Calcd for C₂₆H₂₇N₃O₂. 1.64% H₂O: C, 74.28; H, 6.66; N, 9.99. Found: C, 73.94; H, 6.77; N, 9.82.

EXAMPLE 14 2-(4-Methyl-l-piperazinyl)ethyl l-phenyl-1,2- ihydro[ 1,4] oxazino [ 2,3,4-jk]carbazol-7-yl ether

To a mixture of 7-(2-chloroethoxy)-l-phenyl-l,2-dihydro[l,4]oxazino[2,3,4- jk]carbazole (0.412 g, 1.13 mmol) in dry DMF (10 mL) is added N-methyl piperazine (0.125 mL, 1.13 mmol), sodium iodide (0.17g, 1.13 mmol), and potassium carbonate (0.312g, 2.26 mmol). The mixture is heated at 85 °C for 20 h. The mixture is then cooled and partitioned between water and CH2CI₂. The organic layer is separated and washed twice with water (200 mL), dried over anhydrous sodium sulfate and concentrated. Column chromatography (50 mL silica) using CH₃OH/CH₂Cl₂ (8/92) with 2 drops per 100 mL of NH₄OH gave 0.156 g (32%) of 2-(4-methyl-l- piperazinyl)ethyl l-phenyl-l,2-dihydro[l,4]oxazino[2,3,4-jk]carbazol-7-yl ether; mp 57 °C.

TR (drift) 2934, 2793, 1585, 1496, 1451, 1323, 1311, 1283, 1264, 1240, 1177, 1167, 1150, 790, 737 cm^"1; 1H NMR (CDCl₃) δ 2.35, 2.6, 2.8, 3.1, 4.4, 4.5, 4.6, 5.5, 6.4, 6.6, 7.0, 7.2, 7.4, 7.9. Water (KF), 1.33%. Anal. Calcd for C₂₇H₂₉N₃O₂»1.33% H₂O: C, 74.84; H, 6.89; N, 9.70. Found: C, 74.90; H, 6.93; N, 9.58.

EXAMPLE 17 2-({2-[(l-Phenyl-l,2-dihydro[l,4]oxazino[2,3,4-jk]carbazol-7- yl)oxy] ethyl } amino)- 1 -ethanol

To a mixture of 7-(2-chloroethoxy)-l-phenyl-l,2-dihydro[l,4]oxazino[2,3,4- jk]carbazole (0.273 g, 0.751 mmol) in dry DMF (10 mL) is added sodium iodide (0.113 g, 0.751 mmol), potassium carbonate (0.207 g, 1.5 mmol), and ethanolamine (0.046 g, 0.751 mmol). The mixture is heated at 85 °C for 17 h. The temperature is then increased to 90 °C and the mixture is allowed to stir for another 5 h. The mixture is then cooled to room temperature and partitioned between water and ether. The organic layer is washed twice with water (50 mL), dried over anhydrous sodium sulfate and concentrated. Column chromatography (50 mL silica gel) using 5% methanol in CH₂C1₂ gave 0.123 g (42%) of 2-( { 2- [(1 -phenyl- 1,2- dihydro[l,4]oxazino[2,3,4-jk]carbazol-7-yl)oxy]ethyl}amino)-l-ethanol.

IR (drift) 1584, 1495, 1451, 1351, 1324, 1310, 1267, 1242, 1153, 1086, 1041, 791, 742, 720, 702 cm^"1; ¹H NMR (CDCl₃) δ 3.0, 3.3, 3.7, 4.4, 4.5, 4.6, 5.5, 6.5, 6.7, 7.0, 7.2, 7.4, 7.8. Water (KF), 0.96%. Anal. Calcd for C₂₄H₂ N₂O₃ ^«0.96% H₂O: C, 73.49; H, 6.27; N, 7.14. Found: C, 73.61; H, 6.32; N, 7.10.

EXAMPLE 18 N,N-dimethyl-2-[(l-phenyl-l,2-dihydro[l,4]oxazino[2,3,4- jk]carbazol-7-yl)oxy]-l-ethanamine

To a mixture of 2-chloroethyl l-phenyl-l,2-dihydro[l,4]oxazino[2,3,4- jk]carbazol-7-yl ether (0.248 g, 0.68 mmol) in dry DMF (10 mL) is added potassium carbonate (0.376 g, 2.7 mmol), sodium iodide (0.101 g, 0.68 mmol), and 2M dimethylamine in THF (0.68 mL, 1.36 mmol). The mixture is stirred for 48 h at room temperature. The mixture is then partitioned between water and Et₂θ. The organic layer is washed three times with water (100 mL), dried over anhydrous sodium sulfate and concentrated. Column chromatography (50 mL silica) using CH₂CI₂ followed by CH₃OH/CH2θ₂ (95/5) as eluent and then drying of the appropriate fractions under house vacuum gave 0.020 g (8%) of N,N-dimethyl-2-[( 1 -phenyl- 1,2- dihydro[l,4]oxazino[2,3,4-jk]carbazol-7-yl)oxy]-l-ethanamine; mp 117-118 °C. 1H NMR (CDCI₃) δ 2.82, 3.43, 4.47, 4.60, 4.49, 6.45, 6.61, 6.94, 7.11, 7.32, 7.75.

EXAMPLE 19 2-[(5-Methyl-l-phenyl-l,2-dihydro[l,4]oxazino[2,3,4- jk]carbazol-7-yl)oxy]-l-ethanamine

To a mixture of 2-[(5-methyl-l-phenyl-l,2-dihydro[l,4]oxazino[2,3,4- jk]carbazol-7-yl)oxy]acetonitrile (0.66 g, 1.86 mmol) in dry THF (120mL) is added borane-methylsulfide complex (0.53 mL, 5.6 mmol). The mixture is refluxed at 85 °C for 18 h. The mixture is removed from heat and methanol is slowly added until gas evolution ceased. The solvents are removed under vacuum and methanol (5 mL) is added and again removed. The residue is dissolved in CH₂CI₂/CH₃OH (1:2 15 mL). Cone. HCI (2 mL) is added and the mixture heated at 65°C for 1 h. The mixture is removed from heat and neutralized with aqueous potassium carbonate then partitioned between water and CH₂CI₂. The organic layer is washed with water, dried over magnesium sulfate, and concentrated. Column chromatography (70 g silica gel) using CH₃OH/CH2CI2 (4:96) as eluent gave 0.444 g (67%) of the title compound;

TR (drift) 1593, 1576, 1487, 1448, 1335, 1313, 1261, 1162, 1138, 1129, 1022, 838, 779, 750, 702 cm^"1; 1H NMR (CDC1₃) δ 3.30, 4.25, 4.46, 4.57, 5.48, 6.42, 6.59, 6.93, 7.15, 7.32, 7.83. Anal. Calcd for C₂₃H22N2O2: C, 77.07; H, 6.19; N, 7.82. Found: C, 76.62; H, 6.29; N, 7.68.

PREPARATION 27 4-Chlorobutyl l-phenyl-l,2-dihydro[l,4]oxazino[2,3,4- jk]carbazol-7-yl ether To a mixture of l-phenyl-l,2-dihydro[l,4]oxazino[2,3,4-jk]carbazol-7-ol (0.5 g, 1.66 mmol) in dry DMF (5 mL) is added potassium carbonate (1.15 g, 8.3 mmol) and l-bromo-4-chlorobutane (1.4 g, 8.3 mmol). The mixture is heated at 85 °C, under argon, for 4 h. The mixture is then cooled to room temperature and water (50 mL) is added. The mixture is transferred to a separatory funnel and partitioned between water and ether. The ether layer is washed with water (50 mL) then dried over anhydrous sodium sulfate. The ether filtrates are then concentrated. Column chromatography (50 mL silica) using hexanes followed by hexanes/methylene chloride (1:1) gave 0.373 g (57%) of the title compound.

1H NMR (CDC1₃) δ 2.16, 3.58, 3.71, 4.28, 4.50, 4.60, 5.52, 6.43, 6.62, 6.95, 7.16, 7.34, 7.84.

EXAMPLE 20 N,N-Diethyl-N-{4-[(l-phenyl-l,2-dihydro[l,4]oxazino[2,3,4- jk]carbazol-7-yl)oxy]butyl } amine

To a mixture of 4-chlorobutyl 1-phenyl-l ,2-dihydro[l ,4]oxazino[2,3,4- jk]carbazol-7-yl ether (0.36 g, 0.9 mmol) in dry DMF (10 mL) is added potassium carbonate (0.63 g, 4.6 mmol), diethylamine (0.48 mL, 4.6 mmol), and sodium iodide (0.135 g, 0.9 mmol). The mixture is heated at 50 °C for 20 h. The mixture is then cooled to room temperature and partitioned between water and ether. The ether layer is washed twice with water (50 mL) then dried over anhydrous sodium sulfate and concentrated. Column chromatography (60 mL silica) using 5% methanol in methylene chloride as eluent gave 0.127 g (33%) of the title compound.

TR (liq.) 2967, 2933, 1587, 1496, 1458, 1451, 1431, 1323, 1311, 1264, 1239, 1152, 1042, 790, 737 cm^"1. 1H NMR (CDC1₃) δ 1.11, 1.87, 1.99, 2.68, 4.24, 4.50, 4.60, 5.51, 6.42, 6.62, 6.94, 7.17, 7.34, 7.85; Anal. Calcd for Czs^NzOz: C, 78.47; H, 7.53; N, 6.54. Found: C, 78.27; H, 7.68; N, 6.47.

PREPARATION 28 3-Chloroρropyl l-phenyl-l,2-dihydro[l,4]oxazino[2,3,4- jk]carbazol-7-yl ether To a mixture of l-phenyl-l,2-dihydro[l,4]oxazino[2,3,4-jk]carbazol-7-ol (0.82 g, 2.7 mmol) in dry DMF (12 mL) is added l-bromo-3-chloropropane (1.28 g, 8.1 mmol) and potassium carbonate (1.12 g, 8.1 mmol). The mixture is heated at 80 °C for 6 h. The mixture is then stirred at room temperature for 18 h followed by another 6 h at 80 °C. The mixture is partitioned between water and CH₂CI₂. The organic layer is washed 3 times with water (100 mL). The organic layer is then dried over anhydrous sodium sulfate and concentrated. Column chromatography (60 mL silica) using hexanes/ CH₂CI₂ (1 : 1) as eluent gave an oil which is rechromatographed (60 mL silica) using hexanes / CH C1₂ (60/40) as eluent gave 0.454 g (44%) of the title compound. IR (drift) 1585, 1497, 1451, 1349, 1323, 1311, 1263, 1239, 1178, 1150, 1040,

790, 737, 718, 699 cm^"1. 1H NMR (CDC13) δ 2.44, 3.54, 3.90, 4.29, 4.39, 4.5, 4.6, 5.5, 6.4 6.65, 6.95, 7.16, 7.34, 7.79; Anal. Calcd for C₂3H20CINO2: C, 73.11; H, 5.34; N, 3.71; Cl, 9.38. Found: C, 70.92; H, 5.32; N, 3.55.

EXAMPLE 21 N,N-Diethyl-N-{3-[(l-phenyl-l,2-dihydro[l,4]oxazino[2,3,4- jk]carbazol-7-yl)oxy]propyl ] amine

To a mixture of 3-chloropropyl l-phenyl-l,2-dihydro[l,4]oxazino[2,3,4- jk]carbazol-7-yl ether (0.45 g, 1.2 mmol) in dry DMF (10 mL) is added diethylamine (1.2 mL, 12 mmol) and sodium iodide (0.18 g, 1.2 mmol). The mixture is heated at 50 °C overnight. The mixture is partitioned between water and CH₂CI₂. The layers are separated and the organic layer washed with brine (50 mL) followed by water (100 mL). The organic layer is dried over anhydrous sodium sulfate, filtered and concentrated. Column chromatography with silica gel (60 mL) using CH3OH CH₂CI₂ (3/97) as eluent gave 0.216 g (43 %) of the title compound.

TJR (liq.) 2968, 1587, 1578, 1496, 1459, 1451, 1431, 1324, 1312, 1265, 1240, 1179, 1152, 791, 738 cm^"1. 1H NMR (CDCI3) δ 1.12, 2.18, 2.66, 2.85, 4.25, 4.4), 4.), 5.51, 6.4), 6.63, 6.94, 7.16, 7.32, 7.86; Anal. Calcd for C₂₇H₃oN₂O₂ + 0.27 % H2O: C, 78.02; H, 7.30; N, 6.74. Found: C, 77.41; H, 7.34; N, 6.70.

PREPARATION 29 2-Chloroethyl (lR)-l-phenyl-l,2-dihydro[l,4]oxazino[2,3,4- jk]carbazol-7-yl ether

To a mixture of (lR)-l-phenyl-l,2-dihydro[l,4]oxazino[2,3,4-jk]carbazol-7-ol

(3.67 g, 12.19 mmol) in DMF (90 mL) is added potassium carbonate (8.4 g, 60.9 mmol) and l-bromo-2-chloroethane (5.0 mL, 60.9 mmol). The mixture is heated to 85 °C for 24 h. The temperature is then increased to 95°C and heated for 4 h. Mechanical stirring is employed and the reaction heated an additional 1.5h. The mixture is then partitioned between water and Et₂θ. The layers are separated and the organic layer washed with water (100 mL). The organic layer is dried over anhydrous sodium sulfate, filtered and concentrated. Column chromatography with silica gel using hexane/CH₂Cl₂ (60 /40) gave 2.4 g (54%) of the title compound.

TR (drift) 1637, 1585, 1497, 1450, 1431, 1323, 1311, 1265, 1239, 1151, 1040, 790, 738, 718, 700 cm^"1. [ ]²⁵ _D = -86° (c 0.85, methylene chloride). 1H NMR (CDC1₃) δ 3.85, 4.02, 4.5, 4.6, 5.51, 6.45, 6.60, 6.96, 7.16, 7.34, 7.91; Anal. Calcd for C₂₂H₁₈ClNO₂: C, 72.62; H, 4.99; N, 3.85; Cl, 9.74. Found: C, 69.28; H, 4.95; N, 3.55

EXAMPLE 22 [(2-{[(lR)-l-Phenyl-l,2-dihydro[l,4]oxazino[2,3,4- jk]carbazol-7-yl]oxy}ethyl)amino]ethanol

To a mixture of 2-chloroethyl (lR)-l-phenyl-l,2-dihydro[l,4]oxazino[2,3,4- jk]carbazol-7-yl ether in DMF (20 mL) is added sodium iodide (1.0 g, 6.7 mmol), potassium carbonate (2.0 g, 14.5 mmol), and ethanolamine (0.42 mL, 7.0 mmol). The mixture is heated to 85°C for 18 h. The mixture then is partitioned between water and CH₂CI2. The layers are separated and the organic layer washed twice with water (200 mL). The organic layer is dried over anhydrous sodium sulfate, filtered and concentrated. Column chromatography with silica gel (60 mL) using CH₃OH CH₂CI₂ (2/98) and then rechromatographed with CH₃OH/CH₂Cl₂/NH₄OH (4/96/0.1) gave 0.62 g (24%) of the title compound.

IR (drift) 1585, 1496, 1451, 1348, 1323, 1311, 1265, 1239, 1151, 1070, 1041, 790, 738, 718, 699 cm^"1. % Water (KF): 0.73. [α]²⁵ _D = -78° (c 0.77, methylene chloride). 1H NMR (CDC13) δ 2.97, 3.24, 3.71, 4.33, 4.49, 4.60, 5.51, 6.44, 6.63, 6.95, 7.16, 7.33, 7.80; Anal. Calcd for C₂ H₂₄N₂O₃ with 0.73 % H₂O: C, 74.21; H, 6.23; N, 7.21. Found: C, 73.51; H, 6.47; N, 7.04. 5-HT₆ RECEPTOR BINDING ASSAY

Growth of Cells and Membrane Preparation

Hela cells containing the cloned human 5-HT₆ receptor were acquired from Dr. David R. Sibley's laboratory in National Institute of Health (see Sibley, D.R., Neurochemistry. 66, 47-56, 1996). Cells were grown in high glucose Dulbecco's modified Eagle's medium, supplemented with L-glutamine, 0.5% sodium pyruvate, 0.3% penicillin-streptomycin, 0.025% G-418 and 5% Gibco fetal bovine serum and then were harvested, when confluent, in cold phosphate buffered saline.

Harvested intact cells were washed once in cold phosphate-buffered saline. The cells were pelleted and resuspended in 100 ml of cold 50 mM Tris, 5 mM EDTA and 5 mM EGTA, pH 7.4. Homogenization was with a Nir Tishear generator, 4 cycles for 30 seconds each at setting 50. The homogenized cells were centrifuged at 700 RPM (1000 X g) for 10 minutes and the supernatant was removed. The pellet was resuspended in 100 ml of the above buffer and rehomogenized for 2 cycles. The rehomogenized cells were then centrifuged at 700 RPM (1000 X g) for 10 minutes and the supernatant was removed. The combined supernatant (200ml) was centrifuged at 23,000 RPM (80,000 X g) for 1 hour in a Beck an Rotor (42.1 Ti). The membrane pellet was resupended in 50-8- ml of assay buffer containing HEPES 20 mM, MgC12 10 mM, ΝaCl 150 mM, EDTA lmM, pH 7.4 and stored frozen in aliqouts at -70°C.

5-HT₆ Receptor Binding Assay

The radioligand binding assay used [ H] -lysergic acid diethylamide (LSD). The assay was carried out in Wallac 96-well sample plates by the addition of 11 μl of the test sample at the appropriate dilution (the assay employed 11 serial concentrations of samples run in duplicate), 11 μl of radioligand, and 178 μl of a washed mixture of WGA-coated SPA beads and membranes in binding buffer. The plates were shaken for about 5 minutes and then incubated at room temperature for 1 hour. The plates were then loaded into counting cassettes and counted in a Wallac MicroBeta Trilux scintillation counter. Binding Constant (Ki) Determination

Eleven serial dilutions of test compounds were distributed to assay plates using the PE/Cetus Pro/Pette pipetter. These dilutions were, followed by radioligand and the bead-membrane mixture prepared as described above. The specifically bound cpm obtained were fit to a one-site binding model using GraphPad Prism ver. 2.0. Estimated IC₅₀ values were converted to Ki values using the Cheng-Prusoff equation (Cheng, Y. C. et al., Biochem. Pharmacol.. 22, 3099-108, 1973). The Ki values obtained from the assay are shown in Table 1.

TABLE 1: 5-HT₆ receptor Binding Assay Data

Blood-Brain Barrier Penetration

Pharmacokinetics of the compounds of formula I can be evaluated in mice to determine the ability of each compound to penetrate the blood-brain barrier. Each mouse receives a single intravenous administration at 5 mg/kg. Blood samples are collected by serial sacrifice at 5 min (IN only), 0.5, 1, 2, 4, and 8 h after dosing with two mice per collection time. Blood was placed into tubes containing heparin and centrifuged for plasma. Brain samples were also collected at 0.5 and 1 h increments from the same mouse used for blood collection. Plasma and brain samples were analyzed for drug concentrations using a LC-MS/MMS method. Pharmacokinetics (clearance, volume of distribution, and half -life) were evaluated from the plasma concentration-time data (See Gibaldi and Perrier in Pharmacokinetics, Nol I, 2^nd ed, New York: Marcel Dekker, 1982). Compounds having a large volume of distribution will have good distribution into the body tissues. Comparison of the drug concentration in brain and plasma (brain/plasma ratio) provides the direct information of brain penetration. Higher numbers refer to higher brain penetration.

Claims

CLAMSWhat is claimed is

1. An isotopically labeled compound of formula I

I or a pharmaceutically acceptable salt or enantiomer thereof wherein

R. is

(a) H, or

(b) halo;

R₂ is

(a) H, or

(b) C_1-6 alkyl;

R₃ is (a) -(CH₂)_m-NR₈R₉;

R^ is

(a) aryl; aryl is phenyl or naphthyl, optionally substituted with one or more Rio; Each R₈ and R is independently (a) H,

(b) Cι_₆ alkyl optionally substituted with -OH,

(c) CHO, provided that only one of R₈ and R₉ is CHO and the other is H, and

(d) R₈ and R taken together with the nitrogen to which they are attached form a five-, six-, or seven-membered heterocyclic ring wherein the heterocyclic ring includes an additional heteroatom N(Y);

Y is H or C_1-6 alkyl;

(a) halo, (b) -OH, (c) -CN,

(d) -CF₃,

(e) Ci_₆ alkyl, or

(f) -NH₂; and m is 2, 3 or 4; and wherein the compound of formula I includes an isotopic label.

2. The compound of claim 1, wherein Ri is H or chloro.

3. The compound of claim 1, wherein R₂ is H or methyl.

4. The compound of claim 1, wherein R₃ is -(CH₂)₂-NR₈R₉, wherein R₈ and R is independently H, - alkyl optionally substituted with -OH, or R₈ and R₉ taken together with the nitrogen to which they are attached form piperazinyl, wherein one of the nitrogen atoms on the piperazinyl ring is substituted with H or Cι_-4 alkyl.

5. The compound of claim 1, wherein R₃ is -(CH₂)₂~NR₈R₉, wherein R₈ and R₉ is independently H, methyl, ethyl, ethanol, or R₈ and R₉ taken together with the nitrogen to which they are attached form 4-methyl-l -piperazinyl.

6. The compound of claim 1, wherein R₄. is phenyl.

7. The compound of claim 1 , wherein the compound has at least one atom selected from Carbon-11, Nitrogen- 13, Oxygen- 15, and Fluorine- 18.

8. The compound of claim 1, wherein the compound is selected from N-methyl-2- [( 1 -phenyl- 1 ,2-dihydro [ 1 ,4]oxazino [2,3 ,4-jk]carbazol-7-yl)oxy]- 1 - ethanamine;

2-[(l-phenyl-l,2-dihydro[l,4]oxazino[2,3,4-jk]carbazol-7-yl)oxy]ethanamine; N-ethyl-2- [( 1 -phenyl- 1 ,2-dihydro[ 1 ,4] oxazino [2,3 ,4-jk]carbazol-7-yl)oxy]ethanamine; 2-[(8-chloro-l-ρhenyl-l,2-dihydro[l,4]oxazino[2,3,4-jk]carbazol-7- yl)oxy]ethanamine; 7- [2-(4-methylpiperazin- 1 -yl)ethoxy] - 1 -phenyl- 1 ,2-dihydro [ 1 ,4] oxazino [2,3 ,4- jk]carbazole;

2-( { 2-[( 1 -phenyl- 1 ,2-dihydro[ 1 ,4] oxazino [2,3 ,4-jk]carbazol-7- yl)oxy]ethyl } amino)ethanol; N-ethyl-2- [(5-methyl- 1 -phenyl- 1 ,2-dihydro[ 1 ,4] oxazino [2,3 ,4-jk]carbazol-7- yl)oxy]ethanamine;

N,N-dimethyl-2- [( 1 -phenyl- 1 ,2-dihydro[ 1 ,4] oxazino [2,3 ,4-jk]carbazol-7-yl)oxy]- 1 - ethanamine;

2- [(5-methyl- 1 -phenyl- 1 ,2-dihydro[ 1 ,4]oxazino [2,3 ,4-jk]carbazol-7-yl)oxy]- 1 - ethanamine;

N,N-diethyl-2- [( 1 -phenyl- 1 ,2-dihydro[ 1 ,4] oxazino[2,3 ,4-jk]carbazol-7-yl)oxy] - 1 - ethanamine; and enantiomers and pharmaceutically acceptable salts thereof, wherein the compound has an isotopic label.

9. The compound of claim 8, wherein the isotopic label is Carbon- 11, Nitrogen- 13, or Oxygen- 15.

10. The compound of claim 1, wherein the compound is (R)-N-methyl-2-[(l- phenyl-l,2-dihydro[l,4]oxazino[2,3,4-jk]carbazol-7-yl)oxy]-l-ethanamine and pharmaceutically acceptable salts thereof, wherein the compound has an isotopic label.

11. The compound of claim 10, wherein the isotopic label is Carbon- 11 , Nitrogen- 13 , or Oxygen- 15.

12. The compound of claim 1, wherein the compound is selected from

2- [( 1 -phenyl- 1 ,2-dihydro [ 1 ,4]oxazino[2,3 ,4-jk]carbazol-7-yl)oxy]ethanamine; N-ethyl-2- [( 1 -phenyl- 1 ,2-dihydro [1 ,4] oxazino [2,3 ,4-jk]carbazol-7-yl)oxy]ethanamine; 2- [(8-chloro- 1 -phenyl- 1 ,2-dihydro[ 1 ,4]oxazino [2,3 ,4-jk]carbazol-7- yl)oxy]ethanamine;

N-methyl-2- [( 1 -phenyl- 1 ,2-dihydro [ 1 ,4] oxazino [2,3 ,4-jk]carbazol-7-yl)oxy] - 1 - ethanamine; N-ethyl-2-[(5-methyl-l-phenyl-l,2-dihydro[l,4]oxazino[2,3,4-jk]carbazol-7- yl)oxy]ethanamine;

7-[2-(4-methylpiperazin- 1 -yl)ethoxy]- 1 -phenyl- 1 ,2-dihydro[ 1 ,4]oxazino [2,3 ,4- jk]carbazole; 2-({ 2-[(l-phenyl- 1 ,2-dihydro[l ,4]oxazino[2,3,4-jk]carbazol-7- yl)oxy]ethyl}amino)ethanol;

N,N-dimethyl-2-[(l-phenyl-l,2-dihydro[l,4]oxazino[2,3,4-jk]carbazol-7-yl)oxy]-l- ethanamine;

2- [(5-methyl- 1 -phenyl- 1 ,2-dihydro [ 1 ,4]oxazino [2,3 ,4-jk]carbazol-7-yl)oxy]- 1 - ethanamine;

N,N-diethyl-2- [( 1 -phenyl- 1 ,2-dihydro[ 1 ,4]oxazino [2,3 ,4-jk]carbazol-7-yl)oxy] - 1 - ethanamine; or an enantiomer or pharmaceutically acceptable salts thereof, wherein the compound has an isotopic label.

13. The compound of claim 12, wherein the compound is N-methyl-2-[(l-phenyl- l,2-dihydro[l,4]oxazino[2,3,4-jk]carbazol-7-yl)oxy]-l-ethanamine^»(2Z)-but-2- enedioic acid salt (1:1), wherein the compound has an isotopic label.

14. The compound of claim 12, wherein the compound is 2- [(1 -phenyl- 1,2- dihydro [ 1 ,4] oxazino[2,3 ,4-jk]carbazol-7-yl)oxy]ethanamine^»methanesulfonate salt, wherein the compound has an isotopic label.

15. The compound of claim 12, wherein the compound is N-ethyl-2- [(1-phenyl- l,2-dihydro[l,4]oxazino[2,3,4-jk]carbazol-7-yl)oxy]ethanamine^»(2Z)-but-2-enedioic acid salt (1:1), wherein the compound has an isotopic label.

16. The compound of claim 12, wherein the compound is 2-[(8-chloro-l-phenyl- l,2-dihydro[l,4]oxazino[2,3,4-jk]carbazol-7-yl)oxy]ethanamine^»(2Z)-but-2-enedioic acid salt (1:1), wherein the compound has an isotopic label.

17. The compound of claim 12, wherein the compound is N-ethyl-2- [(5-methyl- 1- phenyl-l,2-dihydro[l,4]oxazino[2,3,4-jk]carbazol-7-yl)oxy]ethanamine^«(2Z)-but-2- enedioic acid salt (1:1), wherein the compound has an isotopic label.

18. The compound of claim 1, wherein the isotopic label is included in the R3 substituent.

19. A method of performing diagnostic screening comprising: incorporating an isotopically labeled compound into tissue of a mammal, wherein the isotopically labeled compound is a compound of any one of claims 1-18.

20. The method of claim 19, wherein the mammal is administered the detectably labeled compound.

21. The method of any one of claims 19-20, wherein the diagnostic screening is positron emission tomography.

22. The method of claim 21, wherein the isotopically labeled compound has at least one atom selected from Carbon-11, Nitrogen- 13, and Oxygen- 15.

23. The method of any one of claims 19-20, wherein the diagnostic screening is single photon emission computed tomography.

24. Use of a compound of any one of claims 1-18 for performing diagnostic screening comprising: incorporating an isotopically labeled compound into tissue of a mammal.

25. The use of claim 24, wherein the mammal is administered the detectably labeled compound.

26. The use of any one of claims 24-25, wherein the diagnostic screening is positron emission tomography.

27. The use of claim 26, wherein the isotopically labeled compound has at least one atom selected from Carbon-11, Nitrogen- 13, and Oxygen- 15.

28. The use of any one of claims 24-25, wherein the diagnostic screening is single photon emission computed tomography.